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Early cardiac involvement is difficult to diagnose in SLE. Autoantibodies have 
been associated with lupus cardiac involvement. A novel 29-kDa heart reactive 
autoantibody was identified in lupus sera by immunoblots, and characterized as 
anti-cTnI (cardiac troponin I) antibody by 2-D electrophoresis and mass 
spectrophotometry of the mouse heart antigen. This was further confirmed by 
competitive inhibition assays. The prevalence of this antibody was found to be 12% 
in a cohort of 109 lupus patients. Immunoblotting results using human heart lysates 
showed concordant results with those obtained by mouse heart lysates. No 
anti-cTnI was detected in the sera of 118 non-lupus rheumatic patients (primary 
antiphospholipid syndrome, rheumatoid arthritis, osteoarthritis, polymyositis) and 
50 patients with acute myocardial infarction. Polymyositis patients and lupus 
patients with myositis showed a positive protein band of 27 kDa, which was 
demonstrated to be similar to skeletal TnI. Clinical data were obtained by chart 
review. Color Doppler echocardiography with measurements of strain and strain 
rates were performed to evaluate cardiac function in the same cohort of lupus 
patients. Anti-cTnI positivity was found to correlate with myocardial dysfunction 
as shown by reduced early diastolic longitudinal strain rates. I postulate that the 
formation of anti-cTnI antibody is the result of chronic, low-grade cardiomyocyte 
damage and may represent sustained early cardiac damage. This antibody may 
serve as an early serological marker for cardiac involvement in lupus patients. 
In this study, I also describe the Interleukin 18 (IL-18) promoter gene 
  x
polymorphisms in a cohort of Chinese SLE patients and the protein levels in the 
circulation. Two single nucleotide polymorphisms at position –607 and –137 of the 
interleukin 18 promoter gene were studied. I found the frequency of genotype 
SNP-607/CC, to be significantly higher in Chinese SLE patients when compared to 
the control individuals. A significant decrease of genotype AC at position –607 was 
also observed in SLE patients compare to the controls. This study also shows that 
SLE patients have significantly higher circulating IL-18 protein levels than normal 
controls. The results also indicate that patients who have anti-cTnI antibody may 
have higher circulating IL-18 proteins.  
 
These findings not only suggest a possible mechanism for cardiac damage in SLE 
patients, but also provide a possible early serological marker for lupus cardiac 
involvements.
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1.1 Systemic lupus erythematosus 
Systemic lupus erythematosus (SLE) is a multi-organ autoimmune disease 
characterized by a wide array of clinical manifestations, from mild skin and 
mucosal lesions to severe inflammation in the central nervous system, kidneys and 
other organs. It involves almost every aspect of immunology and is thought to be 
the archetype of autoimmune diseases. SLE is a very heterogeneous disease, but 
most of its diverse manifestations, including glomerulonephritis, cytopenias, rashes 
and thromboses, are driven by the production of autoantibodies. The overall disease 
prevalence 1.5–250 in 100,000 (Rus and Hochberg 2002) and until the middle of 
the last century, the 5-year survival rate was < 50% (Dubois and Wallace 1987). 
1.1.1 Epidemiology 
Epidemiological studies on SLE show marked gender, age, racial, temporal and 
regional variations, indicating hormonal, genetic and environmental factors are 
disease triggers.  
Firstly, there are striking gender disparities in SLE. Higher disease prevalence in 
women was found compared to men. Based on clinical experiences alone, it was 
established that the disease generally affected females in 80–90% of the cases 
(Siegel and Lee 1973). In a more recent review, the female-to-male ratio in the 
childbearing years was reported to be about 12: 1 (Ramsey-Goldman R 2000). 




Secondly, SLE has population prevalence differences. Danchenko et al.(Danchenko 
et al. 2006b) summarised the results of over 60 such studies. The lowest incidences 
of SLE were seen among Caucasian Americans, Canadians and Spaniards with 
incidences of 1.4, 1.6 and 2.2 cases per 100,000 people respectively. Throughout 
Europe, the highest incidences were found in France (5.0 cases/100,000), Sweden 
(4.7 cases/100,000), and in Asian (10.0 cases/100,000) and Afro-Caribbean (21.9 
cases/100,000) residents of the UK. The prevalence patterns summarised by 
Danchenko et al. (Danchenko et al. 2006b) were similar to those of incidence, but 
no clear North–South or East–West pattern emerged. Studies of aboriginal 
populations in Australia and New Zealand report higher prevalence and incidence 
in this population than in Australian Caucasians. Both racial and genetic differences, 
and more complex social factors related to poverty and access to care are likely 
associated with increased risk of the disease. A higher prevalence of SLE among 
people of sub-Saharan African descent living in North America, the Caribbean and 
Europe, compared with residents of sub-Saharan Africa, was summarised by Bae et 
al. (Bae et al. 1998). They described that SLE prevalence is reportedly low in 
sub-Saharan Africa, while in western countries, these same populations have more 
disease. This phenomenon could be explained by genetic admixture or 
environmental exposures associated with increased risk of SLE, it also might be due 
to competing mortality from other causes in Africa, by the possibility that SLE 




Thirdly, age distribution of SLE cases is usually broad, ranging from children as 
young as two years old to adults 80 years of age and older. However, in females, the 
incidence of the disease is usually highest at 15–44 years of age, while its 
prevalence is maximal at 45–64years (Siegel and Lee 1973). Child bearing age 
females are at highest risk for SLE suggesting a key role for hormonal factors in 
SLE etiology. 
In addition, a temporal increase in SLE burden has been reported by a number of 
researchers. For instance, from 1955 to 1974, the incidence of SLE in the USA 
increased from 1.0 to 7.6 (Fessel 1974; Siegel et al. 1970). Temporal increases may 
be associated with changes in environmental factors, although increased 
recognition of the disease and improved diagnostic methods may lead to apparent 
increases in SLE frequencies. 
The rates of SLE in Europe have been lower than in USA (Johnson. et al. 1995) but 
recent data from USA (McCarty et al. 1995; Ward 2004) makes this difference less 
obvious. The lowest overall incidence was found in Iceland and Japan and highest 
in USA and France. The overall prevalence was the lowest in Northern Ireland, UK 
and Finland, and the highest in Italy, Spain and Martinique. The burden of SLE was 
consistently increased in non-white population of the USA, Europe, Canada and 






1.1.2 Pathogenesis of SLE 
The pathogenesis of SLE relates to abnormalities of both the innate and adaptive 
immune systems. Studies in various model systems, including mouse and human, 
have provided useful insights into the development of this disease. 
1.1.2.1 Genetics 
Murine models of lupus help to understand the human disease process and develop 
alternative therapeutic strategies. 
Firstly, it is possible to breed large numbers of genetically homogenous inbred mice 
under controlled environmental conditions to facilitate largescale genome wide 
linkage analyses. Secondly, the flexibility and manipulatability of murine models 
allow the generation of congenic mouse strains to investigate the effect of given loci 
in different nonlupus prone backgrounds, or the development of knock-outs and 
transgenics to look at the effect of the absence or over expression of 
immunologically relevant genes. Given the significant similarity of the human and 
mouse immune systems, it is anticipated that the linkage studies and functional 
genetics from knock-outs and transgenics accumulated in the mouse models can be 
extrapolated into the human disease studies.  
Mouse models displaying autoimmune phenotypes have provided important 
insights into our understanding of the human SLE. For example, NZB/W F1 mice 
develop spontaneous glomerulonephritis and elevated anti-dsDNA serum levels, 
and MRL-lpr/lpr mice have autoantibody production, lymphadenopathy, 
glomerulonephritis and arthritis (Borchers et al. 2000). Numerous single gene 
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knockout models have developed autoimmune features and experimental crosses 
have emphasized the importance of background genes (epistasis) (Bolland et al. 
2002; Wakeland et al. 2001). Work with the SLE prone NZM2410 strain suggests 
the presence of both susceptibility and suppressor genes, as well as interval specific 
regulation of different aspects of the lupus phenotype (Nguyen et al. 2002). Such 
studies have been essential in exploring mechanisms of immune dysregulation and 
establishing potential genetic contributions. 
A genetic contribution to disease susceptibility is supported by an increased sibling 
risk (as much as 20-fold) and by increased disease concordance in monozygotic 
twins (Alarcon-Segovia and Alarcon-Riquelme 2004; Wakeland et al. 2001). Many 
different genes contribute to disease susceptibility and it has been estimated that 
over 100 genes may be involved in SLE susceptibility (Tsao 2004). 
Homozygous deficiencies of the early components of the complement system could 
lead to development of SLE or a lupus-like disease (Walport et al. 1998). But for 
most of the remaining patients, multiple genes are required. Schur et al estimated 
that at least four susceptibility genes are needed for the development of the disease 
(Schur 1995). 
Of the genetic elements, the major histocompatibility complex (MHC) has been the 
most studied in SLE. Population studies suggest human leukocyte antigen (HLA) 
class II gene polymorphisms are associated with SLE. HLA DR2 and DR3 are 
found to correlate with SLE in different ethnicities (Lindqvist and 
Alarcon-Riquelme 1999; Tsao 2004).  The HLA class II genes have also been 
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associated with the presence of certain autoantibodies such as anti-Sm, anti-Ro, 
anti-La, anti-RNP and anti-DNA antibodies (Schur 1995). 
Deficiencies for early components of the complement pathway are strongly 
associated with the development of SLE and studies have demonstrated an 
association with C4A*Q0, the C4A null allele (Arnett and Reveille 1992). This 
allele is in strong linkage diswquilibrium with the HLA-A1-B8-DRB1*0301 
haplotype, which also carries DQA1*0501 and DQB1*0201 alleles and these have 
been associated with autoantibody production in SLE (Reveille et al. 1991). 
Association between C4B*Q0 and SLE has been repoted in American Blacks 
(Wilson et al. 1988), Australian Aborigines (Christiansen et al. 1991), Chinese 
(Hawkins et al. 1988) and Mexicans (Reveille et al. 1995). An increased frequency 
of C4B*Q0 was also found in a family study of DR3-negative British SLE patients  
(Batchelor et al. 1987). 
For non-MHC genes, the list includes genes encoding mannose binding protein 
(MBP), tumor necrosis factor α, the T cell receptor, interleukin 6 (IL-6), CR1, 
immunoglobulin Gm and Km allotypes, Fc γ receptor IIa and IIIa and heat shock 
protein 70 (Schur 1995; Sullivan 2000). However, in most of the cases, consistent 
results could not be obtained in different ethnic groups.  
For example, many association studies have investigated polymorphisms in the 
stimulatory Fcγ RIIa (CD32) and Fcγ RIIIa (CD16) genes, both of which are low 
affinity binders of IgG molecules. The human orthologues of Fcγ RII and Fcγ RIII 
are located in the 1q23–24 linkage region on human chromosome 1, identified in 
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genome-wide linkage studies for SLE (Gray-McGuire et al. 2000; Moser et al. 
1998). Studies focus on the single nucleotide polymophisms (SNP) in these genes. 
In the case of Fcγ RIIa the nonsynonymous polymorphism converts amino acid 
residue 131 from histidine (H) to an arginine(R), with the R allele binding with less 
avidity to IgG2 than the H allele. Since Fcγ RIIa is the major receptor class for IgG2, 
this missense mutation is important because anti-dsDNA autoantibodies are 
predominantly of the IgG2 subclass, so the mutation may lead to delayed clearance 
of dsDNA-IgG2 containing immune complexes. However, the results of a series of 
association studies investigating the involvement of the R131 allele with lupus 
nephritis were inconclusive. In SLE cases from African American (Salmon et al. 
1996), white Dutch (Duits et al. 1995) and Hispanic populations with high level of 
renal disease(Zuniga et al. 2001), there was increased Fcγ RIIa R131 allele 
compared to the H allele. However, this was not observed in other European, Asian 
or African Caribbean populations both with and without renal disease (Botto et al. 
1996; D'Alfonso et al. 2000; Dijstelbloem et al. 2000; Koene et al. 1998; Manger et 
al. 1998; Salmon et al. 1996; Salmon et al. 1999). In an attempt to clarify the 
inconsistencies of these results, meta-analysis was carried out on genotyping 
information from 17 studies. This analysis showed that the RR genotype was more 
common in the total number of SLE cases (Odds Ratio (OR) =1.30, 95% 
confidence interval (CI) 1.10–1.52) and in those patients without renal disease 
(OR=1.27, 95% CI 1.04–1.55), both compared to normal controls. There was a 
potential dose–response relationship, most clearly seen in the European Caucasian 
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racial group, between the R allele, encoding the low affinity receptor, and the risk of 
SLE, but not for lupus nephritis (Karassa et al. 2003).  
In Fcγ RIIIA, the most frequently studied SNP also leads tononsynonymous amino 
acid change; from phenylalanine (F) to valine (V) change at residue 158. The F158 
allele binds IgG1 and IgG3 with lower affinity than the V158 allele. This is 
important since evidence in both human SLE and in murine models of lupus 
nephritis suggests that IgG2 and IgG3 may have a pathogenic role in kidney disease 
(Takahashi et al. 1991; Zuniga et al. 2003). Consequently, alleles of Fcγ RIIA 
reducing the clearance of IgG3 antibodies may increase the extent of renal disease. 
As with Fcγ RIIA, the results from association studies were not conclusive, with 
increased levels of the low binding F158 allele in reported in Hispanic (Zuniga et al. 
2001), Caucasian (Koene et al. 1998), Korean (Salmon et al. 1999) and an 
ethnically diverse population (Wu et al. 1997), but not in African American (Oh et 
al. 1999) or Caucasian SLE patients (Dijstelbloem et al. 2000). Association of F158 
to lupus nephritis was found in a Caucasian, Korean and a multiethnic population 
(Salmon et al. 1999) but not in Germans or in Hispanics, Asian/Pacific Islanders 
and African Americans (Seligman et al. 2001). A recent meta-analysis of the 
F/V158 polymorphism using data from 11 studies showed association of the 
lowbinding F158 allele with lupus nephritis (OR=1.2, 95% CI 1.06–1.36,P=0.003). 
This risk was higher in FF homozygotes compared to VV homozygotes (OR=1.47, 
95% CI 1.11–1.93, P=0.006). The association to SLE was uncertain (Karassa et al. 
2003). Overall, the association data for the H/R131 and F/V158 polymorphisms is 
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not strong enough to fully account for the linkage identified in 1q23–24, indicating 
that other genes encoded in this region are involved in the genetic susceptibility to 
SLE. 
Recently, polymorphisms in genes for interferon regulatory factor 5 (IRF5) and 
protein tyrosine phosphatase N22 (PTPN22) have been associated with increased 
risk of SLE, shedding some new light on potential mechanisms of disease 
susceptibility and pathogenesis (Baca et al. 2006; Graham et al. 2006; Orozco et al. 
2005). 
1.1.2.2 Environmental factors 
A number of environmental factors may also be involved in the pathogenesis of 
SLE (Deapen et al. 1992). Environmental (or non-genetic) exposures could include 
infectious agents, chemicals or other compounds capable of modulating immune 
responses (Cooper et al. 1999; Edwards 2005) such as occupational/environmental 
pollutants or drugs, and behavioural factors such as smoking and diet (Table 1). 
Environmental exposures may lead to the production of autoreactive T cells and 
autoantibodies, the stimulation of pro- and anti-inflammatory cytokines, and 
end-organ damage (Figure 1). Exposure to viruses such as Epstein-Barr virus 
increases antibody titers, but these may be the result of polyclonal B cell activation 
(Arbuckle et al. 2003a).  
Other data suggest that there may be a link between infections early in life and an 
increased prevalence of antinuclear antibodies and SLE in adults. Early exposure to 
microbial antigens or vaccines may predispose to lupus-like autoimmune disease 
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(Baxter et al. 1994). The amount and timing of exposure to different environmental 
factors may therefore play a significant and complex role in the pathogenesis of 
SLE and other autoimmune diseases (Edwards 2005). 
Ultraviolet radiation (UVR) is one of the most important environmental factors for 
SLE. UV exposure may exacerbate local and systemic autoimmunity by inducing 
changes in the expression and binding of keratinocyte autoantigens (Kuhn and 
Lehmann 2004; Norris 1993). Autoantigen clustering was reported on the cell 
surface of cultured keratinocytes with apoptotic changes due to UV irradiation 
(Casciola-Rosen et al. 1994; Vila et al. 1999). The translpcation of usually 
cell-sequestered autoantigens to the cell surface of apoptotic blebs may allow 
circulating autoantibodies to gain access to them (Vila et al. 1999). And it has been 
suggested that antibody binding to the exposed antigens may lead to tissue injury by 
complement or inflammatory cells (Casciola-Rosen et al. 1994). 
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Table 1. Environmental factors and SLE.  Adapted from "Environment and 
systemic lupus erythematosus: an overview."(Sarzi-Puttini et al. 2005)  
 
Infectious agents 
  *Bacterial DNA/endotoxins 
  *Epstein-Barr virus, cytomegalovirus, Parvovirus B19 
  *Retroviruses 
Occupational exposure and pollutants 
  *Crystalline silica 
  *Solvents 
  *Pesticides 
  *Hair dyes 
  *Heavy metals 
Drugs 
  *Drugs: Procainamide, hydralazine, chlorpromazine, isoniazide, phenytoin, 
penicillamine 
Hormones and environmental estrogens 
  *Hormonal replacement therapy, oral contraceptive pills 
  *Prenatal exposure to estrogens 
Behavioural exposures 
  *Ultraviolet light 
  *Tobacco smoke 
Dietary factors 
  *High Intake of saturated fats 






Figure 1: The role of environment in SLE. Adapted from “Environment and 




The prevalence of systemic lupus erythematosus (SLE) is much higher in females 
than in males and numerous investigations to understand this gender bias have been 
conducted. While it is plausible that some sex-linked genes may contribute to the 
genetic predisposition for the disease, other likely culprits are the sex hormones 
estrogen and prolactin. Potential causes of the female predisposition for SLE 
included the effects of estrogen and its hydroxylation, decreased androgen levels, 




1.1.2.4 Infection and inflammation 
Viral and bacterial infections may serve as an environmental trigger for the 
development or exacerbation of SLE in the genetically susceptible individual.  
Epstein-Barr virus (EBV) is the environmental agent most closely associated with 
SLE. EBV infection is more common in SLE patients (99%) compared to the 
normal population (90%) (Zandman-Goddard and Shoenfeld 2005). In children a 
serologic association of Epstein-Barr virus (with an odds ratio of ~50) has been 
confirmed by an association of lupus with viral Epstein-Barr virus DNA from the 
peripheral blood (James et al. 1997). 
A large study comparing 196 adult SLE patients and 392 matched controls likewise 
found association of previous Epstein-Barr virus exposure with SLE. No consistent 
associations between SLE and other common herpes viruses, such as 
cytomegalovirus, herpes simplex 1, or herpes simplex 2, were found (James et al. 
1997; James et al. 2001). 
Recent research has provided convincing evidence that EBV infection may play a 
major role, not only in molecular mimicry, but also in aberrations of B cell function, 
and apoptosis which is programmed cell death leading to a state of perpetual 
heightened immune response in SLE. 
In a recent study (McClain et al. 2005), 9 of 29 individuals who were susceptible to 
developing SLE harbored the same and only epitope of Ro 69kDa defined by amino 
acids 169-180 (TKYKQRNGWSHK). Samples in early preclinical state, which 
bound to this epitope only, were depleted of additional antibodies against 60 kDa 
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Ro. These purified antibodies consistently recognized EBNA-1, but not other 
autoantigens or dsDNA. In addition, they did not bind to antigens of other common 
viruses. The affinity purified antibodies to TKYKQRNGWSHK all bound to a 
small specific peptide defined region of the EBNA-1 molecule 
(GGSGSGPRHDGVRR, amino acids 58-72). All of the SLE patients in this study 
were positive for antibodies to EBV-VCA or EBNA-1, either prior to or coincident 
with the development of any autoantibody. In addition, 17 patients had antibodies 
to EBNA-1 before antibodies to Ro could be detected. No individual had antibodies 
to Ro before they developed antibodies to EBNA-1. 
 In non-autoimmune individuals following infection with EBV, 18% had antibodies 
that cross react with the peptide of Ro, and only one developed anti-Ro antibodies 
transiently. In order to evaluate if these antigenic structures are pathogenic, New 
Zealand white rabbits (a strain that is incapable of EBV infection) were immunized 
with either the EBV or Ro cross-reactive peptide. These animals rapidly and 
simultaneously developed antibodies to both 60 kDa and EBNA-1, but not to other 
herpes viruses. The peptide immunized animals showed the immunological 
capacity of the Ro and EBNA-1 cross reaction to trigger lupus-like autoimmunity 
and clinical disease manifesting as leukopenia, thrombocytopenia, and an elevation 
in the serum creatinine levels. 
Another study shows cross reactivity between EBNA-1 and anti-Sm and 
anti-dsDNA antibodies. The EBNA-1 gene was cloned under the control of the 
CMV promoter in the vector pcDNA3. For the first time, the expression of the 
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entire EBNA-1 protein in the mouse was shown to elicit the production of IgG 
antibodies to Sm and to dsDNA (Sundar et al. 2004).  
Recent EBV infection or virus reactivation was occurring in SLE patients whose 
sera were tested for antibodies to several EBV antigens and had a significantly 
higher prevalence of immunoglobulin G antibodies against EBV early antigens 
than in normal or disease controls (Huggins et al. 2005).  
Other than EBV, it has been known that parvovirus B19 and cytomegalovirus 
infections induce a number of autoimmune abnormalities resembling those found in 
SLE (Hsu and Tsay 2001; Pugliese et al. 2007; Sekigawa et al. 2002). 
Hepatis C virus was reported to correlate lupus (Chen et al. 2005; Feng et al. 2006; 
Lormeau et al. 2006; McMurray and Elbourne 1997; Qin et al. 2002). In a study, the 
prevalence of HCV infection was found to be higher in SLE patients than in 
non-SLE subjects.  SLE patients with positive HCV showed a lower rate of 
cutaneous SLE and positive dsDNA antibody, but have higher incidences of hepatic 
damage, hypocomplementemia and cryglobulinemia (Qin et al. 2002).  
On the other hand, SLE patients are more prone to developing common infections 
such as pneumonia, urinary tract infection, cellulitis, sepsis, chronic infections e.g. 
tuberculosis and opportunistic infections. It is probably due to inherited genetic and 
immunologic defects. Complement deficiencies, mannose-binding lectin (MBL) 
polymorphisms, elevated Fc gamma receptor III and GM-CSF levels, osteopontion 
polymorphism were all possible pathogenetic factors (Zandman-Goddard and 
Shoenfeld 2005).  
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In addition, use of broad-spectrum immunosuppressive agents for severe 
manifestations of the disease could contribute to increased infection risks in SLE 
patients (Gladman et al. 2002).  
Infections in SLE patients remain a significant cause of morbidity and mortality. A 
caveat often encountered is to distinguish between a lupus flare and an acute 
infection; in such cases parameters including elevated CRP (and adhesion 
molecules) may aid in the differentiation between the two.  
1.1.2.5 Immunology 
The pathogenesis of SLE, a heterogeneous disease, involves all aspects of 
immunology: antigen presentation, production of autoantibodies, immune tolerance 
and immune clearance (Figure 2). 
The disease progresses through four broad stages, that is, the presence of 
autoantibodies against a variety of ubiquitous self-antigens, deposition of 
autoantibodies and immune complexes in tissues, development of tissue 
inflammation and finally, tissue damage and fibrosis.  
Firstly, dysregulated immune function plays an important role in SLE. Animal 
models suggest that self-reactive B and T cells exist in the normal immune 
repertoire but are kept in control to avoid pathological autoimmunity. These control 
mechanisms are defective in lupus mice, which have impaired activation of such 
inhibitory, suppressor and regulatory T cells (Richards et al. 2001).  Impairments in 
CD8+ T cell suppressor functions have also been described in human SLE (Filaci et 
al. 2001). Natural killer T cells that co-express the NK receptor and invariant T cell 
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receptor (TCR) are reduced in numbers and exhibit impaired functions in lupus 
mice before the onset of clinical disease (Yang et al. 2003). 
Secondly, antigen-processing and presentation abnormalities are also present. 
Studies have identified impairments in antigen-presenting cell functions in lupus. 
Dendritic cells and macrophages display increased maturation and contribute to T 
cell hyperactivity in a mouse model of lupus (Zhu et al. 2005). 
 
Figure 2: Roadmap to disease development and progression in SLE. 
Adapted from"SLE: translating lessons from model systems to human disease." 
(Singh 2005). The lupus disease progresses through a series of steps: (1) immune 
dysregulation and (2) immunity against self generally occur long before the onset of 
the first symptoms that are manifestations of (3) autoimmune ‘invasion’ and (4) 
consequent inflammation. The autoimmune disease up to this stage is generally 
amenable to correction by the defenses of the body or by anti-inflammatory or 
immunosuppressive treatments. (5) Some patients, however, exhibit impaired 
tissue response to inflammation or have local or systemic factors that perpetuate 
tissue fibrosis and organ damage. The patients at stage (5) and beyond generally do 




 Immune dysregulation (e.g. Deficiency of suppressor cells and factors) 
Autoreactive T cell activation
B cell activation
Tissue inflammation 
(e.g. early inflammatory lupus nephritis) 
Tissue Fibrosis
Organ damage and death
Uncontrolled production of cytokines 










Furthermore, Langerhans cells in MRL/lpr mice exhibit impaired migration to 
draining lymph nodes (Eriksson and Singh 2006). Importantly, correction of this 
defect results in improved lupus dermatitis (Eriksson and Singh 2006; Yang et al. 
2003) 
Thirdly, T cell and B cell abnormalities may be the best-studied topics in SLE 
pathogenesis. T cells from lupus patients and mice exhibit intrinsic T cell 
abnormalities such as diminished T cell activation thresholds and dysregulated 
apoptosis. Animal studies showed that there is excessive co-stimulation between T 
cell-B cell-APC through the CD40-CD40L or CD28-B7 pathways in lupus 
(Hoffman 2004). Genetic depletion of B cells leads to amelioration of murine lupus, 
suggesting a crucial role for B cells in lupus (Shlomchik and Madaio 2003).  
Fourthly, production of autoantibodies with different specificities may cause tissue 
and organ damage in SLE. Certain murine anti-DNA antibodies interact with 
antigens in the glomerular basement membrane or hippocampal neurons, leading to 
death or dysfunction of local cells, such as podocytes or neurons, respectively (Izui 
et al. 1976; Kowal et al. 2004). The autoantibody and immune complex deposition 
triggers the activation of the complement cascade, chemotaxis and infiltration with 
immune cells, resulting in local inflammation. Cytokines are also involved in the 
progression of tissue and organ damage. In this regard, MRL-lpr mice that develop 
predominant inflammatory disease have high levels of interferon-γ (IFN-γ), 
whereas NZM.2410 mice that develop severe glomerulosclerosis have high in vivo 
levels of IL-4 (Singh 2003). 
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1.1.2.6 Immune clearance deficiency 
The humoral immune response in SLE has been used as a marker of disease activity 
and anti-double stranded DNA is the main autoantibody. However, human DNA is 
known to be poorly immunogenic and does not bear T cell epitopes which could 
initiate T-cell help for DNA-recognizing B cells.  In SLE patients, DNA-histone 
complexes and nucleosomes are released in high amounts, which are targets of 
anti-DNA autoantibodies and of anti-histone autoantibodies (Amoura et al. 1994; 
Burlingame and Rubin 1990; Rumore and Steinman 1990; Steinman 1984). These 
autoantibodies are predominantly of IgG isotype and molecular analysis reveals a 
high degree of somatic mutation in their VH regions. These are unique features of 
an antigen-driven immune response (Radic and Weigert 1993). The presence of 
histone-specific T-cells in SLE patients (Voll et al. 1997) reinforces the theory that 
nuclear material derived from apoptotic or necrotic material may serve as an 
important source of autoantigens. 
There are two main forms of cell death, namely apoptosis and necrosis. The initial 
stimulus and the microenvironment determine whether cells die through apoptosis 
or necrosis. Apoptosis is an active, programmed and regulated cellular process 
which appears under both physiological and pathological conditions in all tissues. 
Apoptosis plays a critical role in the maintenance of a balance between old and new 
cells in states of high-rate tissue turnover like embryogenesis and development 
(Majino and Joris 1995; Skulachev 2002). Apoptosis consists of an enzymatic chain 
reaction that, once triggered by the appropriate stimuli, leads to the activation of 
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several intracellular proteases and DNases, which finally degrade intracellular 
material in an orderly way. The membrane of apoptotic cells shows characteristic 
and important changes in the arrangement of phospholipids and sugars. Moreover, 
it remains intact during this process, thereby preventing the release of intracellular 
components. Finally, cell shrinkage and membrane blebbing constitute the final 
stages of the apoptotic process (Cohen 1993). These morphological and 
biochemical changes of dying cells are important for their clearance from tissues by 
the scavenger system. Therefore, the recognition, removal and fate of these cells 
depend highly upon the stage of the apoptotic process (Savill and Fadok 2000). If 
these cells are not cleared on time, they lose their membrane integrity and become 
secondarily necrotic, thereby releasing high amounts of modified nuclear and 
cytoplasmic material (reviewed in (Sheriff et al. 2004)). 
 In this case, inflammation and induction of immune responses against newly 
formed nuclear antigens are possible. Cell death by necrosis, on the other hand, 
occurs when external factors affect cells. A violent interruption of their vital 
functions and finally a disruption of the plasma membrane are the consequences. 
This phenomenon is often triggered by an infectious agent, heat, UV radiation, 
ischaemia, low ATP levels or a mechanical injury. 
Intracellular content is then released without cleavage, favouring inflammation and 
tissue damage (Ren and Savill 1998). Under normal conditions, the apoptotic or the 
necrotic cell materials are quickly removed by a highly efficient scavenger system 
(macrophages, polymorphonuclear cells (PMN) and immature dendritic cells) 
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(Surh and Sprent 1994).  
Both apoptotic and necrotic cells expose ‘eat me’ signals that flag them for their 
removal from tissues by phagocytes. One of the earliest changes in apotosis is the 
exposure of phosphatidylserine (PS) and phosphatidylethanolamine on the outer 
leaflet of the membrane. Necrotic cells also expose PS in the outer membrane 
because the ATP-dependent mechanism that maintains membrane asymmetry is 
disrupted (Brouchaert et al. 2003). PS is then recognized by several receptors of 
phagocytic cells: the vitronectin receptor (Savill et al. 1990), the β2-glycoprotein-1 
receptor (Cheng 1996), scavenger receptors (SR) such as CD36 (Savill et al. 1992), 
CD68 (Ramprasad et al. 1995) and class A scavenger receptors (SR-A) (Platt et al. 
1998), the ATP-binding cassette transporter 1 (ABC1) (Luciani and Chimini 1996), 
the lectin-like oxidized low-density lipoprotein receptor 1 (LOX-1) (Oka et al. 
1998), the lipopolysaccharide receptor CD14 (Devitt et al. 1998), and the putative 
PS receptor (Fadok et al. 2000). This recognition occurs directly between PS and a 
receptor on phagocytes or indirectly through bridging molecules that act as 
opsonizing agents (reviewed in (Hart et al. 2004)). 
There is growing evidence for a clearance deficiency of early apoptotic cells in 
mouse models of SLE (Licht et al. 2004; Taylor et al. 2000) and in humans 
(Baumann et al. 2002; Herrmann et al. 1998). In the later stages of apoptosis, 
apoptotic cells also become “leaky”. They are then called secondary necrotic cells, 
and can release DNA-containing nucleosomes together with dangerous 
inflammatory signals towards immune system cells (Kuenkele et al. 2003; Rovere 
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et al. 2000). Furthermore, it has been shown that the high mobility group B1 
(HMGB1) protein, which is attached to the chromatin of apoptotic cells, remains 
immobilized even under conditions of secondary necrosis, while in the case of 
primary necrotic cells it is released and acts as an inflammatory cytokine 
(Rovere-Querini et al. 2004; Scaffidi et al. 2002). Therefore, primary and secondary 
necrotic cells display different inflammatory signals. 
Complement and DNase I contribute to an efficient clearance of dying cells. 
DNase1 deficiencies generate autoantibodies to chromatin and glomerulonephritis 
and a spontaneous lupus-like syndrome (Napirei et al. 2000). Data collected from 
knockout mouse models of molecules involved in the clearance process shows that 
accumulation of apoptotic cells in tissues together with an immune response against 
DNA-containing complexes is the common denominator between them 
(Bickerstaff et al. 1999; Boes et al. 2000; Botto et al. 1998). Deficient phagocytic 
activity for yeast and bacteria is found in human SLE patients (Salmon et al. 1984). 
Macrophages from SLE patients are impaired in the phagocytosis of autologous 
apoptotic material in vitro (Herrmann et al. 1998). These evidence support the 
hypothesis that impairment of the physiological disposal of cellular debris 
predisposes to the development of SLE.  
SAP protein is a member of the pentraxin family and is constitutively present in 
serum at a concentration of 40ug/ml. During inflammation in normal mouse, levels 
can rise to 50 times the normal level. SAP binds to extracellular matrix components, 
to C1q and to C4 binding protein, and shows specific binding activity to DNA, 
Introduction 
 24
nuclear chromatin and nucleic compounds released during necrosis. Interaction of 
SAP with nuclei leads to the solubilization of nuclear chromatin (Pepys et al. 1978). 
The exact target of SAP on apoptotic cells is not yet clear. Studies carried out in 
SAP-/- mice show retardation in the degradation of chromatin exposed by dead 
cells and an enhanced anti-DNA response when mice are immunized with extrinsic 
chromatin (Bickerstaff et al. 1999). This favours the role of SAP in the clearance of 
chromatin and chromatin-related debris when they are not properly cleared from 
tissues in early phases of cell death (Gaipl et al. 2003). 
1.1.2.7 Autoantibodies in SLE  
The diagnosis of SLE is mostly based on clinical criteria, including skin rashes, 
photosensitivity, non-erosive arthritis, oral ulcers, serositis, glomerulonephritis and 
neurological disorders, as well as on the presence of antibodies to certain 
autoantigens, such as double-stranded (ds) DNA, Smith (Sm) and phospholipids. 
The phenotypic heterogeneity associated with SLE diagnosis can be attributed to 
both genetic and environmental factors. 
Autoantibody production can be the harbinger of autoimmune disease, especially in 
the case of disease-specific autoantibodies, which may appear months, years, or 
even decades before the onset of clinical symptoms (Arbuckle et al. 2001). 
Detection of disease-specific autoantibodies in asymptomatic individuals may 
permit earlier diagnosis and treatment. 
A variety of autoantibodies have been reported to precede the onset of SLE (Satoh 
et al. 1995; Vlachoyiannopoulos et al. 1998). ANA, anti-Ro, anti-La, and 
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antiphospholipid antibodies may be present for extended periods before the onset of 
autoimmune disease, whereas anti-Sm and anti-nRNP are thought to appear much 
closer to the onset of disease (Arbuckle et al. 2003b).  Anti-dsDNA antibodies are 
intermediate. In one study using stored serum samples from military recruits, 55% 
of individuals who subsequently developed SLE had positive anti-dsDNA 
antibodies. Anti-dsDNA antibodies were detected as long as 9.3 years before 
diagnosis, with a mean of 2.7 years (Arbuckle et al. 2001). In the same cohort, at 
least one lupus autoantibody was present before diagnosis in 88% of patients, and 
ANA were present in 78% (Arbuckle et al. 2003b). Thus, many cases of lupus are 
preceded by asymptomatic serological abnormalities. However, the likelihood that 
asymptomatic individuals with lupus autoantibodies will develop SLE has yet to be 
worked out. 
Among these autoantibodies, ANA is the most frequently used to screen for SLE. 
The sensitivity of a positive fluorescent ANA test for lupus could reach 90% to 95% 
(Emlen and O'Neill 1997; Tan et al. 1982). However, the specificity is low and the 
positive predictive value is only 11-13% (Edworthy et al. 1988; Slater et al. 1996). 
By contrast, Anti-Sm, anti-dsDNA, and antibodies against the ribosomal P antigens 
(P0, P1, and P2), are highly specific for SLE. Increasing anti-dsDNA antibody 
levels may herald exacerbations of lupus nephritis or other organ involvement, and 
it has been suggested that corticosteroid therapy may be warranted to prevent flares 
in patients with an increasing anti-dsDNA antibody titer, even in the absence of 
other clinical evidence (Bootsma et al. 1995).  
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Anti-Sm antibodies are considered to be pathognomonic of SLE and are detected in 
approximately 7-25% of lupus patients, depending on ethnic origin (Reeves et al. 
2004). Unlike anti-dsDNA, the levels of anti-Sm antibodies do not correlate with 
disease activity. Anti-nRNP antibodies are associated with anti-Sm (virtually all 
anti-Sm sera are anti-nRNP positive), but are not disease specific. Their prevalence 
in SLE is 20-40%. Antiribosomal P antibodies are reportedly associated with 
neuropsychiatric manifestations of lupus (Bonfa et al. 1987), although this is 
somewhat controversial (Teh and Isenberg 1994). They are, however, specific for 
the diagnosis of SLE.  
1.1.2.8 Pathogenesis of cardiovascular involvements in SLE 
Since the end of 18th century it has been recognized that the heart can be affected 
during the course of various rheumatic conditions. Heart involvement was first 
described in patients with rheumatic fever (RF) by David Pitcairn, in an 
unpublished communication at St Bartholomew’s Hospital in London (1788), as 
reported by Matthew Baillie (Baillie 1797). Jean-Martin Charcot described heart 
manifestations in rheumatoid arthritis in 1874 (Charcot 1897) and William Osler in 
systemic lupus erythematosus (SLE) in 1895 (Osler 1859). The description of 
atypical verrucous endocarditis in SLE by Emauel Libman and Benjamin Sacks in 
1924 also represents a clear milestone (Libman and Sacks 1924). At the beginning 
of the 20th century, the involvement of the vascular system with the description of 
Raynaud’s phenomenon, and some diseases characterized by inflammatory changes 
of vessel walls also became evident.  
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Currently, cardiovascular manifestation in lupus attracts more attention as it has 
emerged as a major cause of mortality and morbidity. 
1.1.2.8.1 General cardiovascular manifestations 
Pericarditis 
Pericarditis is one of the most characteristic disease manifestations and is included 
as one of the ACR classification criteria for SLE. Endocardiographic studies show 
pericardial abnormalities in between 11% and 54% SLE patients (Doria et al. 2004). 
The pericardium can be involved by acute and chronic inflammatory changes. 
Acute pericarditis can be serofibrinous or fibrinous. In chronic pericarditis, the 
fibrous or fibrofibrinous aspects prevail. Granular deposition of immunoglobin and 
C3 are demonstrated by direct immnofluorescence, supporting the role of 
immunocomplexes in the development of pericarditis (Bidani et al. 1980). 
Pericardial involvement appears more frequently at SLE onset or during SLE 
relapses. Complications of pericarditis, such as cardiac tamponade, constrictive 
pericarditis and purulent pericarditis are rare.  
Valvular abnormalities 
Libman-Sacks endocarditis is the most characteristic lesion affecting the heart 
valves (Libman et al, 1924). Valvular thickening and regurgitation are more 
frequent than verrucous endocarditis. 
Anatomical lesions were observed in 15-75% of cases in necroscopy studies (Doria 
et al. 2004), in 40-50% of cases with the transthoracic echocardiography (TTE) and 
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in 50%-60% with transesophageal echocardiography (TEE) (Omdal et al. 2001). 
Anatomical abnormalities are generally found in the mitral and aortic valves 
(Omdal et al. 2001). Histological findings can be categorized into two groups: (1), 
active lesions which consist of fibrin clumps, focal necrosis and mononuclear cell 
infiltrates, more frequently observed in young patients with recent disease onset 
and rarely lead to hemodynamically significant valvular lesion; (2), healed lesions 
found in patients with long-standing disease and with long term corticosteroids use, 
characterized by vascularized fibrous tissue with calcifications (Doherty and Siegel 
1985). These groups of patients always have functional valve abnormalities, 
especially valvular insufficiency.  
There are two hypotheses to explain the pathogenesis of valvular abnormalities in 
SLE patients: (1), antiphospholipid (aPL) and anti-endothelial antibodies bind to 
activated endothelial cells, leading to platelet aggregation with thrombus formation; 
(2) immunocomplexes deposit between the endothelium and the basal membrane, 
leading to an infiltration of inflammatory cells. 
Jansen-Urstad et al (Jensen-Urstad et al. 2002) recently reported a close association 
between valvular abnormalities and cardiovascular disease as well as raised levels 
of homocysteine and triglycerides in SLE patients, which suggests that patients 
with valvular disease should be screened for clinical and subclinical atherosclerotic 
features.  
Myocarditis 
Myocarditis leads to myocardial dysfunction in SLE. The common use of 
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corticosteroid therapy reduces myocarditis, with clinically overt cases occurring in 
7-10% cases (Bulkley and Roberts 1975; Roberts and High 1999). However, 
necropsy studies show the prevalence of myocarditis at 40-70%, suggesting that 
subclinical cardiac involvement is common. The gold standard in diagnosing lupus 
myocarditis is endocardial biopsy, which is an invasive procedure and has 
procedure-related risks.  
Immunofluorescence studies demonstrate fine granular immunecomplexes and 
complement deposition in the walls and perivascular tissues of myocardial blood 
vessels (Bidani et al. 1980) supporting the postulate that lupus myocarditis is an 
immunecomplex-mediated vascular phenomenon. Some reports demonstrate an 
association between anti-Ro/SSA antibodies and myocarditis (Logar et al. 1990). 
Coronary artery disease (CAD) 
The prevalence of CAD has been reported as ranging from 6% to 10% (Petri et al. 
1992; Toloza et al. 2004) and, in SLE patients, the risk of developing CAD is 4–8 
times higher than controls. In women between the age of 35 and 45, the risk of 
myocardial infarction is increased 50-fold (Kao and Manzi 2002) . 
There are two major histological findings: (1) large transmural infarctions 
frequently due to atherosclerotic plaque of at least one of the three major extramural 
coronary arteries and less due to embolism; (2) small areas of necrosis adjacent to 
small intramural coronary arteries the lumen of which appear restricted and walls 
infiltrated by inflammatory cells. Different mechanisms are at play in the 
development of CAD. These include atherosclerosis, coronary arteritis, thrombotic 
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events with or without aPL, vasospasm or embolization of valvular material and 
hypertension (Bulkley and Roberts 1975; Doherty and Siegel 1985). Manifestations 
of CAD include angina pectoris, myocardial infarction and sudden death. In SLE 
patients, distinction between atherosclerosis and coronary vasculitis is difficult, but 
important for therapeutic decisions. Atherosclerosis accounts for the majority of 
cases of coronary artery disease in SLE patients, whereas arteritis and 
thromboembolic events are comparatively uncommon. 
1.1.2.8.2 Factors contributing to cardiovascular disease in SLE 
There are many factors contributing to cardiac damage in SLE. Environmental 
factors, inflammation, cytokines, hormones and the traditional risk factors for 
cardiovascular disease are all involved.  
The non-specific risk factors for cardiovascular disease in SLE include elevated 
serum cholesterol levels, diabetes mellitus, smoking, obesity, hypertension, and 
sedentary lifestyle (Petri et al. 1992).  
However, even after controlling for these risk factors, SLE disease itself was found 
to be independently associated with cardiovascular events (Esdaile et al. 2001) 
supporting the hypothesis that traditional Framingham risk factors do not fully 
account for the elevated and premature risk seen in SLE patients, and that other 
factors, i.e. inflammatory mediators, abnormal lipoprotein profiles, and oxidative 
damages may also be important in the development of these complications. Other 
risk factors reported in SLE patients include older age at diagnosis, longer disease 
duration, higher cumulative corticosteroid (CS) dose, anti-phospholipid antibodies, 
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elevated homocysteine levels, male sex and renal insufficiency (Manzi et al. 1999; 
Petri 2000).  
Table 2.  Possible Factors contributing to cardiovascular disease in SLE 
 
 







Disease or treatment related Glucocorticoid use 
Renal disease 
Elevated homocysteine levels 
Immunologic/inflammatory Pro-inflammatory cytokines 
Complement-fixing immune complexes 
B cell- T cell interactions 
Antiphospholipid antibodies 
Other unknown heart reactive autoantibodies
 
1.1.2.8.3 Heart reactive autoantibodies in SLE 
Autoimmunity has been associated with cardiac damage by many studies. As Early 
as 35 years ago, anti-heart antibodies detected by immunofluorescence were 
described and considered to represent a non-specific immunologic response to 
altered myocardial antigen released into the circulation following SLE myocarditis 
(Das and Cassidy 1973). In fact, several autoantibodies can mediate cardiac damage: 
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this is the case with antiphospholipid antibodies (aPL), anti-Ro/SS-A antibodies, 
anti-endothelial cells antibodies, and so on (Tincani et al. 2005). 
Caforio et al found circulating autoantibodies in patients with autoimmune 
myocarditis/dilated cardiomyopathies (DCM). These autoantibodies are directed 
against multiple antigens, some of which are expressed in the heart (organ-specific), 
others in heart and some skeletal muscle fibers (partially heart specific) or in 
skeletal muscle (muscle-specific). Distinct autoantibodies have different 
frequencies in patients and normal controls. Cardiac and disease-specific IgG 
antibodies for myocarditis/DCM, can be used as autoimmune markers for 
identifying patients in whom immunosuppression may be beneficial and close 
relatives who are at risk (Caforio et al. 2006; Caforio et al. 2002; Caforio et al. 
1992).  
Anti-SSA/Ro antibodies are associated with congenital heart block (CHB). When 
anti-SSA/Ro antibodies are present in sera of mothers with connective tissue 
diseases, the incidence of CHB has been reported to be 1% to 2% of live births 
(Brucato et al. 2001). The risk of CHB in a subsequent child is 10% to 16% 
(Brucato et al. 2001). Complete heart block is the usual case though first or second 
degree blocks have been observed. In some cases, CHB is associated with 
endocardial fibroelastosis. Late-onset cardiomyopathy may occur later in life in 
these children. 
Antiphospholipid antibody  was reported to correlate with pulmonary hypertension 
(PH), which is a rare but severe complication in patients with systemic lupus 
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erythematosus (SLE) and other connective tissue diseases such as systemic 
sclerosis (SSc) (Hachulla and Coghlan 2004; Steen 1998), mixed connective tissue 
diseases (MCTD), and to a lesser extent, RA (Helmers et al. 1991), idiopathic 
inflammatory myopathies (IIM), and primary Sjögren’s syndrome (pSS).  
The PH may occur in the absence of any other manifestations of the 
antiphospholipid syndrome (APS), and cases have been recorded with very high 
levels of antiphospholipid antibodies. It may also accompany systemic lupus 
erythematosus (SLE) and may manifest with or without other features of the APS. 
The prevalence of pulmonary hypertension (PH) in lupus is  about 0.5–14% (Pan et 
al. 2000; Perez and Kramer 1981; Quismorio et al. 1984; Tanaka et al. 2002; 
Winslow et al. 1995). In a recent study, using a cutoff of 40mmHg for RVSP 
measured by Doppler echocardiography, Johnson et al.(Johnson et al. 2004) found 
a prevalence of 14% in a cohort of 129 patients with SLE, similar to estimates in 
systemic sclerosis. The etiology of PH in patients with SLE is multi-factorial and 
arteriopathy involving the pulmonary vasculature, with increasing pulmonary 
vascular resistance and vasoconstriction, is felt to play a role (Asherson et al. 1990). 
The commonest cardiac manifestation in lupus is chest pain from pleurisy or 
pericarditis. Valvular abnormalities, myocarditis and CAD may also occur. 
Immunofluorescence studies demonstrate granular immunocomplexes and 
complement deposition in the pericardium and myocardial blood vessels, which 
support the hypothesis that cardiac damage is an immunecomplex-mediated 
phenomenon (Bidani et al. 1980). In valvular abnormalities, aPL and 
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anti-endothelial antibodies play important roles by binding to and activating 
endothelial cells, leading to platelet aggregation with thrombus formation. 
Furthermore, immunecomplexes deposit between the endothelium and the basal 
membrane, leading to an infiltration of inflammatory cells, which further contribute 
to vessel damage. Some reports demonstrate an association between anti-Ro/SSA 
antibodies and myocarditis (Logar et al. 1990). Different mechanisms work 
together leading to CAD. These include atherosclerosis, coronary arteritis, 
thrombotic events with or without aPL, vasospasm or embolization of valvular 
material and hypertension (Bulkley and Roberts 1975; Doherty and Siegel 1985). 
More recently, some novel risk factors for atherosclerosis have been proposed and 
reviewed (Doria et al. 2004). They are inflammatory markers (CRP and other 
pentraxines), immunological factors (anti-beta2 glycoprotein I, anti oxidized LDL, 
anti-heat shock protein 60/65). 
The following are some important auto-antigens studied in SLE cardiac 
involvements. 
Cardiac myosin heavy chain 
Cardiac muscle contraction results from cyclical interactions between the 
contractile proteins myosin and actin via a complex chemomechanical coupling 
process supported by the hydrolysis of ATP. Cardiac myosin is a hexamer 
consisting of 2 myosin heavy chains (MHCs) and 2 pairs of myosin light chains 
(MLCs). There are 2 MHC isoforms expressed in the myocardium, the ß-MHC and 
the -MHC isoforms. 
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Cardiac myosin heavy chain is the major autoantigen associated with autoimmune 
myocarditis both in human and in experimental autoimmune myocarditis (EAM) in 
mice. 
Heat shock proteins 
Heat shock proteins occur ubiquitously in prokaryotic and eukaryotic cells, have 
essential functions under normal growth conditions, and play a role in 
immunological response (Cotto and Morimoto 1999). High levels of autoantibodies 
against 60-kDa members of the hsp60 family were associated with 
atherosclerosclerotic vascular diseases (Birnie et al. 1994; Xu et al. 1999; Xu et al. 
1993). Prohászka Z et al (Prohaszka et al. 2001) and others (Zhu et al. 2001) 
recently demonstrated an association between autoantibodies to human hsp60 and 
both the presence and the severity of coronary artery disease (CAD). 
Veres A et al (Veres et al. 2002) measured anti-hsp antibodies to human hsp60 
(anti-hsp60) and mycobacterial hsp65 (anti-hsp65) and anti-cholesterol antibodies 
(ACHA) in a prospective nested case-control study of HOPE study patients to 
determine whether these factors predicted cardiovascular outcomes. They also 
examined the relationship with other inflammatory and infectious risk markers. 
They found that serum antibodies to hsp65 were associated with subsequent 
cardiovascular events in this study of high-risk patients, independent of 
conventional cardiovascular risk factors and other inflammatory markers. 
Anti oxidized LDL autoantibodies 
Atherosclerosis is a chronic inflammatory process of the arterial wall associated 
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with systemic and local immune responses to various antigens, oxidized 
low-density lipoprotein (oxLDL) being the most significant. Both IgM and IgG 
antibodies to oxLDL are produced during atherosclerosis. Some studies have shown 
that elevated levels of antibody to oxLDL correlate with severity of atherosclerosis 
(Binder et al. 2003). Other studies reported that immunization of experimental 
animals with oxLDL induces high levels of antibodies to oxLDL, with decreased 
atherosclerosis (Binder et al. 2002), suggesting that the immune response to oxLDL 
may be antiatherogenic (Shoenfeld et al. 2004). In humans, a growing body of 
evidence indicates that aOxLDL are low at an early stage of CVD development in 
nonautoimmune disease and in healthy individuals (Hulthe et al. 2001; Karvonen et 
al. 2003; Wu et al. 1999) but raised at later stages and in more advanced disease 
(Binder et al. 2002; Lopes-Virella et al. 1999; Salonen et al. 1992; Svenungsson et 
al. 2001). 
OxLDL interacts with beta2GPI via oxLDL-derived specific ligands, such as 
7-ketocholesteryl-9-caboxynonanoate (oxLig-1) to form complexes. In vitro, 
anti-beta2GPI autoantibodies bind to oxLDL/beta2GPI complexes that are actively 
taken up by macrophages via Fc gamma receptors (Matsuura et al. 2002). 
Circulating oxLDL/beta2GPI complexes were detected in patients with systemic 
lupus erythematosus (SLE) and APS (Kobayashi et al. 2003). Autoantibodies 
against these complexes were also present: IgG anti-oxLDL/h2GPI complexes 
autoantibodies and their immune complexes were detected only in SLE/APS 
patients and in its animal model and were strongly associated with arterial 
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thrombosis(Kobayashi et al. 2003). In contrast, IgM anti-oxLDL antibodies derived 
from hyperlipidemic mice reduced the incidence of atherosclerosis. The 
distribution patterns of IgG and IgM anti-oxLDL antibodies in patients suggest 
different roles for these antibodies (Binder et al. 2002). 
1.1.2.8.4 Interleukin-18 and cardiovascular involvements in systemic lupus 
erythematosus 
Interleukin-18 is a proinflammatory cytokine. IL-1 β -converting enzyme 
(caspase-1) cleaves pro-IL18 to an active 18-kDa glycoprotein (Ghayur et al. 1997) 
that recognizes a heterodimeric receptor, consisting of unique α(IL-1Rrp) and 
nonbindingβ(AcPL) signaling chains (Torigoe et al. 1997). IL-18 is expressed by 
various cell types, including macrophages, dendritic cells, keratinocytes, 
osteoblasts, pituitary gland cells, adrenal cortical cells, intestinal epithelial cells, 
skin cells, and brain cells (Dinarello 1999; Stoll et al. 1998). 
The primary functions of IL-18 include the induction of IFN-γ and TNF-α in T 
cells and natural killer cells, up-regulation of Th1 cytokines including IL-2, 
granulocyte macrophage colony-stimulating factor (GM-CSF) and IFN-γ , 
stimulation of the proliferation of activated T cells, and enhancement of Fas ligand 
expression in NK and cytotoxic T lymphocytes. 
Increased levels of circulating interleukin (IL)-18 have proven to be a strong and 
independent predictor of cardiovascular death in patients with coronary artery 
disease (Blankenberg et al. 2002). Clinical and experimental studies have 
demonstrated increased levels of circulating IL-18 following acute myocardial 
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infarction (Mallat et al. 2002) and in the congestive heart failure syndrome (Naito et 
al. 2002; Seta et al. 2000a). Moreover, increased levels of IL-18 and IL-18 
receptor-α have been reported in myocardial tissues from patients with end-stage 
heart failure (Mallat et al. 2004).  
Some other evidence also supports the view that IL-18 plays an important role in 
myocardial dysfunctions. Firstly, IL-18 induces synthesis of tumor necrosis factor 
(TNF)-α (Puren et al. 1998b), IL-1β (Puren et al. 1998a), IL-6 (Olee et al. 1999), 
and inducible nitric oxide synthase (Olee et al. 1999), mediators that have all been 
associated with myocardial dysfunction (Brady 1993; Brady et al. 1993; Finkel et al. 
1992; Kumar et al. 1996); Secondly, IL-18 helps to activate T lymphocytes (Dao et 
al. 1998; Okamura et al. 1995) and induce neutrophilic cell infiltration (Leung et al. 
2001),  as well as stimulation of intercellular adhesion molecule(ICAM)-1 (Kohka 
et al. 1998);  thirdly, it might also exert direct effects on the cardiomyocyte level. 
Both alterations in Ca2+ handling as well as reduced myofilament responsiveness 
to Ca2+ have been reported to be mechanisms of myocardial dysfunction (Atar et al. 
1995b). Fourthly, IL-18 may also play a role in cardiac remodeling by inducing 
hypertrophy of cardiomyocytes in vitro following activation of 
phosphatidylinositol 3-kinase (PI3K), phosphoinositide-dependent kinase-1 
(PDK1), Akt, and GATA-4 signaling. Also, increased atrial natriuretic peptide 
(ANP) expression in isolated cardiomyocytes has been demonstrated after IL-18 
exposure (Chandrasekar et al. 2005b; Seta et al. 2000b); Fifthly, after a short IL-18 
exposure in vitro,  increased calcium transients (diastolic and peak ) and reduced 
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contractility of cardiomyocytes were observed (Woldbaek et al. 2003). And daily 
injection of IL-18 in healthy mice induces LV contractile dysfunction and blunted 
β-adrenergic responsiveness to isoproterenol. And IL-18 reduces the 
responsiveness of the myofilaments to Ca2+ (Woldbaek et al. 2005).  
Giedraitis et al (Giedraitis et al. 2001) first reported that IL-18 promoter gene 
polymorphisms influenced the expression of IL-18 mRNA and potentially also 
IFN-γ expression after stimulation with PMA/ionomicin. Two single nucleotide 
polymorphisms at position –607 and –137 in the promoter gene region were 
considered significant because the change from cytosine to adenine (C to A) at 
position –607 disrupts a potential cAMP-responsive element binding (CREB) 
protein-binding site and a change at position –137 from guanine to cytosine (G to C) 
changes the H4TF-1 nuclear factor binding site to a binding site for an unknown 
factor found in the GM-CSF promoter (Montminy M et al, 1997;Dailey L et al, 
1988).  
Increased IL-18 circulating level was found in SLE patients (Amerio et al. 2002; 
Robak et al. 2002). It is therefore interesting to hypothesize that the genetic 
polymorphisms in the promoter fene region may be associated with cardiovascular 
involvements in SLE.  
1.2 Diagnostic approaches of cardiovascular involvements in SLE  
The diagnosis of cardiac manifestation of lupus is largely dependent on clinical 
features as described above. 
However, owing to the development of new treatment regimens, which have 
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prolonged the life of SLE patients, cardiac abnormalities which are usually 
clinically silent have new importance (Nihoyannopoulos et al. 1990). At the same 
time, although myocardial abnormalities are frequent in autopsy studies, clinically 
patent myocarditis occurs in less than 10% of patients (Moder et al. 1999), which 
means clinical features are insufficient to diagnose cardiovascular involvement in 
SLE. 
There are several Imaging techniques which provide good evaluations of the heart 
chambers and valvular changes in SLE patients. Prognostic information that is 
obtained by cardiac imaging techniques can help in the management of these 
disorders and, therefore, improve the outcome in cardiovascular patients.  
Generally cardiac imaging techniques can be divided into three categories.(1) 
non-invasive imaging technique such as echocardiography, and radio nuclei 
perfusion imaging; (2) semi-invasive imaging, including transesophageal 
echocardiography; (3) invasive imaging, such as angiography.  
The invasive approach such as angiography is less commonly used compared to 
non-invasive ones to evaluate patients. 
1.2.1 Echocardiography 
1.2.1.1 Transthoracic echocardiography (TTE) and transesophageal 
echocardiography (TEE) 
Transthoracic echocardiography is the most commonly used cardiac imaging 
technique. 2D and Doppler echocardiography are able to detect myocardial 
abnormalities including valvular abnormalities, pericardial diseases and regional or 
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global left ventricular defects. Doppler-derived mitral and pulmonary venous flow 
velocities can determine left ventricular diastolic filling and diastolic functions. 
Diastolic filling abnormalities are broadly classified at their extremes as impaired 
relaxation and restrictive physiology with many patterns in between. In patients 
with a mitral Doppler inflow pattern of delayed relaxation, there will be changes 
with a lengthening of the E-wave deceleration time and a decrease in the E/A ratio.  
And the Grade II diastolic dysfunction is characterized by mitral inflow signals that 
are similar to that of the normal state: rapid early inflow (increased E wave) and less 
prominent flow at atrial contraction (A wave). The deceleration time may be 
shortened.  
In the latter stage of diastolic deterioration, left ventricular chamber compliance is 
severely impaired such that there is a larger increase in pressure for small increases 
in ventricular volume.  
Recently, new echocardiography parameters derived from tissue Doppler imaging, 
is considered as a more reliable method to access systolic and diastolic dysfunction. 
Transesophageal echocardiography study is a more sensitive approach than 
transthoracic echocardiography for detecting valvular lesions. It can also help to 
identify intracardiac masses. In a recent TEE five-year follow-up study (Turiel et al. 
2005) in PAPS (primary antiphospholipid syndrome) patients, valvular lesions were 
observed in 13 (27.6%) patients: mitral valve thickening in five out of 13 (38.5%), 
aortic valve thickening in six out of 13 (46.1%) and both valves in two of 13 
(15.4%) subjects. Embolic sources were detected in five (10.6%): four (80%) 
Introduction 
 42
developed marked spontaneous echocontrast and only one (20%) Libman–Sacks 
endocarditis. New cardiac involvements were observed in 17 (36.2%) patients: high 
IgG aCL titer was detected in 15 out of 17 (88.2%) subjects and low IgG 
anticardiolipin (aCL) titer only in two of 17 (11.8%) cases. The importance to 
assess echocardiographic study in PAPS patients is due to the relationship between 
cardiac abnormalities and high aCL titer as reported by several authors (Cervera 
2000; Turiel et al. 2000). 
1.2.1.2. Myocardial contrast echocardiography 
Myocardial contrast echocardiography (MCE) is an emerging technique in which 
microbubble contrast agents are visualized in the coronary microvasculature. MCE 
is an ideal modality for the noninvasive evaluation of acute coronary syndromes 
because it provides portable, simultaneous assessment of regional wall motion and 
myocardial perfusion. Studies suggest a promising role for MCE in the evaluation 
of chest pain, the diagnosis and prognosis in acute myocardial infarction, the 
assessment of the success of reperfusion and the differentiation of myocardial 
stunning from myocardial necrosis. Potential future applications of MCE in acute 
coronary syndromes include the detection of inflammation and ultrasound induced 
thrombolysis (Becher et al. 2000). 
But since cardiac imaging can only detect valvular or vessels abnormalities that 
have developed maturely, it is not a good way to diagnose early cardiovascular 




1.2.1.3 Doppler Tissue Imaging (DTI) 
The differences between conventional Doppler echocardiography and Doppler 
tissue imaging are the following:  
(1) Unlike conventional Doppler signals that are typified by high velocity and low 
amplitude, myocardial motion is characterized by relatively low velocity and high 
amplitude signals. Tissue motion creates Doppler shifts that are approximately 40 
dB higher than Doppler signals from blood flow whereas velocities rarely exceed  
20 cm/s (Isaaz et al. 1989; Sutherland et al. 1994). 
(2) Compared to conventional Doppler echocardiography, which has limitation due 
to “pseudo-normalization” and preload dependence, Doppler Tissue Imaging is a 
better tool for the study of diastolic function in a more direct and less 
preload-dependent manner.  
The myocardium is composed mainly of cardiomyocytes, connected by interstitial 
tissue. Myofibrils are the basic unit for active contraction and relaxation. They are 
imbedded in the cardiomyocytes. The changes of intracellular calcium 
concentration govern the actin-myosin interaction which determine a cycle of 
contraction and relaxation (Braunwald et al. 2001). These changes themselves 
result from sequential activation of calcium channels and pumps, requiring 
hydrolyzation of ATP (adenosine triphosphate) and consequently oxygen. The rate 
and extent of this contraction-relaxation cycle depend on molecular integrity of the 
contractile and calcium regulating proteins and are modulated by neurohumoral 
stimuli (Braunwald et al. 2001; Brutsaert et al. 1993). Relaxation of the ventricular 
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myocardium is influenced by restoring forces (recoil) and visco-elasticity, 
enhancing and impeding its rate and extent, respectively (Leite-Moreira and 
Gillebert 1994). To a certain degree, myocardial contraction and relaxation are 
coupled, oxygen-requiring, sensitive to adrenergic tone and related to structural 
integrity of the cardiomyocytes and the interstitium. 
When myocardial relaxation is approaching completion, myocardial elastic 
properties (compliance) will become much more important. On the ventricular level, 
global diastolic filling is mainly related to the active and passive myocardial 
properties. Dyssynergy in relaxation between different walls, ventricular 
interdependence, coronary engorgement and pericardial constraint further 
determine filling dynamics. 
A normal pattern of DTI consists of 3 major signals: a single systolic signal (S’) and 
2 distinct signals in early (E’) and late (A’) diastole, timed by the onset of early 
inflow and atrial contraction, respectively. A’ represents the passive myocardial 
distension caused by the atrial contraction, either by retraction of the annular ring or 
due to the ensuing late ventricular filling. As E’ represents myocardial distension 
during early diastole, its velocity relates to the velocity of relaxation and its time 
velocity integral to the total displacement during early filling.  
E’ is a good index of LV relaxation and appears to be less sensitive to alterations in 
preload (Sohn et al. 1997). An E’ value of less than 8 cm/s is consistent with 
diastolic dysfunction.  Nagueh et al (Nagueh et al. 1997) correlated an E/E’ >10 
with the presence of diastolic abnormality. Similar to the E/Vp ratio, the E/E’ ratio 
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correlates well with LV filling pressures. An E/E’ ratio greater than 15 was highly 
specific for elevated LA pressures, whereas an E/E’ ratio of less than 8 was highly 
sensitive for normal LA pressures. E/E’ has also been validated in patients with 
sinus tachycardia (Nagueh et al. 1998), atrial fibrillation (Nagueh et al. 1996), 
hypertrophic cardiomyopathy (Nagueh et al. 2001), and those who underwent 
cardiac transplant (Mankad et al. 1999). 
1.2.1.4 Strain and Strain Rate 
Traditionally, cardiac ultrasound has quantified regional myocardial function by 
combining visual analysis of wall motion with the measurement of wall thickening 
and thinning. The measurement of either regional velocity or strain (ε) or strain rate 
(SR) indices by color Doppler myocardial imaging has recently been proposed as a 
possible alternative, as experimental studies have confirmed that, for normal 
myocardium, changes in both segmental systolic velocities and deformation are 
closely linked to changes in contractility (Yamada et al. 1998).  
Myocardial strain is a dimensionless index of change in myocardial length in 
response to an applied force and is expressed as fractional or percent change (Figure 
3). SR is the time derivative of strain with unit of per second (s-1) and in ultrasound 
represents the differential velocity of 2 points normalized for the distance between 
them (Figure 4). By convention, myocardial lengthening or thinning gives a 
positive strain value and shortening or thickening gives a negative value (Pislaru et 




For 1-dimensional strain 
 
 




in which ∆L is the change in length, ∆t is time taken for change in length, L0 is the 
original length, and v is velocity. 
 
Figure 3. Schematic illustrating concept of strain and strain rate (SR). 
Adapted from "Clinical applications of strain rate imaging." (Yip et al. 2003) 
ε is change in length normalized to initial length of muscle (upper left corner). Thus, 
decrease in length (such as occurring in muscle contraction) would result in 
negative strain, increase in length (muscle relaxation) would result in positive strain, 
and rate at which length changes occur would be SR. L0, Initial length of muscle; 
L1, final length. 
 
Myocardial velocity profiles as a method to detect abnormal regional function, 
using motion to represent function has two important drawbacks: (1) peak velocity 
measurement is dependent on the angle at which the region of interest is imaged; 
and (2) overall heart motion, cardiac rotation, and contraction in adjacent segments 
can influence regional velocity estimates. Strain and strain rate could overcome 
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these problems, each reflecting differing aspects of myocardial deformation and 
both relatively independent of overall heart motion. 
SR reflects the relative motion of neighboring regions within the sample volume 
whereas tissue velocity reflects movement relative to the transducer and is hence 
subject to artifacts of tethering and cardiac translation (Urheim et al. 2000). The 
ability of SR imaging to characterize regional deformation rates quantitatively in 
normal and abnormal myocardium has been demonstrated (Jamal et al. 2001; 
Pislaru et al. 2001). Experimental studies confirm that changes in segmental 
systolic deformation are closely linked to changes in contractility measured by 
sonomicrometry (Sebag et al. 2005; Urheim et al. 2000) and that early diastolic SR 
correlates with τ (time constant of isovolumic relaxation), regional myocardial 
stiffness constant and extent of interstitial fibrosis (Park et al. 2006). 
However, there are also limitations. With the currently available technology, strain 
rate has a relatively poor signal to-noise ratio and is load sensitive (Urheim et al. 
2000). Strain measurements are made along a single ultrasound scan line. Three 
dimensional TDE may overcome this limitation (Lange et al. 1997). Limitations 
related to complex fibre architecture and to translation and rotations of the heart 
apply to all imaging modalities. Off-line analyses are required for colour images, 






Figure 4.  Example of strain rate (SR) image. Adapted from "Clinical 
applications of strain rate imaging."  (Yip et al. 2003) 
Single wall color 2-dimensional image of ventricular septum (upper left). SR 
tracing (right middle) shows negative systolic wave (s), positive early diastolic 
wave (e), second positive late diastolic wave (a), and diastasis (d). Waves are 
represented by yellow-red (systole), blue-white (diastole), and green (no muscle 
length change in diastasis) (upper right). In color M-mode tracing: upper, apical; 
middle, mid; lower, basal segments (separated by horizontal dashed lines). 
Electrocardiogram (ECG) trace (lower right). Dashed line in center of septum, level 
of color M-mode display (upper right tracing). 
 
1.2.2 Cardiac troponin I  
Troponin is a complex of three regulatory proteins: troponin T (TnT), troponin I 
(TnI) and troponin C (TnC), involved in the calcium-modulated interaction of actin 
and myosin. 
Cardiac TnI (cTnI), with a unique N-terminal, 31 amino acid sequence, is present 
only in the cardiac muscle and therefore is 100% specific for heart cellular damage. 
Raised cardiac troponin concentrations are now accepted as the gold standard 
biochemical markers for the diagnosis of myocardial damage for several reasons. 
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Firstly, these abundant cardiac structural proteins are not detected in significant 
levels in healthy individuals and are released only during cardiac damage. Secondly, 
following cardiac injury, cTnT and cTnI are released for much longer and therefore 
are detectable in the blood for a long(er) time (up to 5 days for cTnI and up to 7–10 
days for cTnT), unlike CK and CK-MB. Finally, in addition to their diagnostic role, 
these molecules have a prognostic value and can be considered for early risk 
stratification in patients with unstable coronary disease (Wu and Lane 1995). They 
may serve as indicators for therapeutic strategies (Iliou et al. 2003; Lindahl et al. 
1997; Luscher et al. 1997). Moderate elevation of cardiac troponins is also observed 
in clinically stable chronic renal failure patients without significant myocardial 
damage. The exact mechanism is still unknown.  
Troponin I occurs naturally as cardiac, slow skeletal muscle and fast skeletal 
muscle isoforms. There is a switch in troponin I isoform expression during cardiac 
development; the major isoform in early fetal heart is ssTnI which is replaced by 
cTnI late in fetal development (Sabry and Dhoot 1989a, b; Saggin et al. 1989). The 
cardiac isoform differs from skeletal muscle isoforms in that it has an extended 
N-terminal sequence. This N-terminal region contains a serine residue which is 
phosphorylated during the phosphorylation-mediated regulation of contraction by 
P-adrenergic agonists in the heart(Solaro et al. 1976) 
cTnI is part of the troponin complex that regulates actin-myosin interaction which 
plays a key role in the complex contraction-relaxation cycle of cardiac myofibrils. 
Contraction occurs as a result of sliding and interdigitating of the thick and thin 
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filaments of sarcomeres. Contraction is initiated when cytosolic calcium rises and 
binds the troponin complex and alpha tropomyosin, releasing troponin I inhibition 
of actin-myosin interactions. During diastole, active (intramyocardial) processes 
occur in addition to passive (extramyocardial) mechanisms (Zile and Brutsaert 
2002). Within cardiac myocytes, major active events include Ca2+ regulation, 
alteration of myofilament structure and function, and neurohormonal activation. 
Evidence supports a modified theory of excitation-contraction coupling wherein a 
substantial portion of the myosin cross-bridges binds weakly to the actin filament in 
the relaxed state (Solaro and Rarick 1998). This weak binding creates a "closed 
state" in which the cross-bridge interaction creates only a non–force-generating 
reaction (Solaro 1999). Troponin I appear to play a crucial role in this regard; intact 
troponin I is necessary to tether actin and maintain diastole.  
The role of cTnI in cardiovascular disease is well recognized. Gene mutations in 
cTnI account for up to 5% of genotyped families with familial hypertrophic 
cardiomyopathy (FHC)(Doolan et al. 2005; Mogensen et al. 2004; Richard et al. 
2003) . A cTnI gene mutation at codon 203, in which glycine is replaced by a serine 
residue (cTnI-G203S), has been reported to cause human FHC, with affected 
members showing clinical features of FHC, and in some cases, supraventricular and 
ventricular arrhythmias (Kimura et al. 1997). The cTnI-G203S mutation is located 
near the COOH-terminal end of the cTnI protein, a region considered important in 
modulating actomyosin kinetics during unloaded sliding, potentially leading to 
enhanced cross-bridge cycling (Parmacek and Solaro 2004). Cellular studies also 
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indicate that the cTnI-G203S mutation may enhance Ca2+ sensitivity of force 
generation (Deng et al. 2003) and disrupts interactions with partner proteins, 
resulting in intracellular Ca2+ dysregulation early in life (Tsoutsman et al. 2006). 
Overexpression of a truncated form of cTnI has been reported to induce cardiac 
dilatation in mice (Murphy et al. 2000a). Recently, linkage analysis also identified 
cTnI gene mutation as the likely disease genetic factor in families with restrictive 
cardiomyopathy and recessively inherited DCM(Mogensen et al. 2003; Murphy et 
al. 2004) .  
Altered function of troponin I due to either ischemia or depletion of cardiac 
troponin I can produce diastolic dysfunction and myocardial hypertrophy (Huang et 
al. 1999; McDonough et al. 1999). A recent study  found that cTnI degradation at 
the C terminus enhances myofilament Ca2+ sensitivity and slows force development 
as well as its relaxation, whereas systolic function is largely preserved (Narolska et 
al. 2006). Another study (Du et al. 2006) found that a point mutation (R192H) in the 
C-terminus of human cTnI causes diastolic dysfunction in transgenic mice, 
manifested by decreased left ventricular end diastolic dimension and increased end 
diastolic dimension in both atria. Hence, cTnI plays an important role in regulating 
diastolic function. 
Sequence homologies with human cTnI are 96.4% for bovine heart, 92.8% for 
mouse and rat heart, 91.4% for rabbit heart, 71.5% for chicken heart, and 57.1% for 
human skeletal muscle (Bairoch and Apweiler 1996). 
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Okazaki et al (Okazaki et al. 2003) found autoantibodies against cTnI in mice 
model of DCM, and administration of monoclononal antibodies against cTnI 
induced heart dilation and dysfunction in wild type mice. The antibodies also 
augmented the voltage-dependent L-type calcium current in normal 
cardiomyocytes. 
Hence cTnI may play a role in the autoimmunity of cardiac damage. 
1.3 Gaps 
The pathogenesis of cardiovascular manifestations in lupus is complex. 
Inflammations, immunocomplexes, complements and cytokines are all thought to 
be involved. The immunocomplexes seem to be important for causing cardiac 
damage. The presence of anti-Ro/SSA antibodies, antiphospholipid antibodies 
(aPL), and the non-organ-specific autoantibodies such as anti-oxLDL, anti-HSP65 
are in some ways involved. However, the exact roles these autoantibodies play in 
the development of cardiovascular abnormalities in SLE is still unknown. 
Questions arise as to whether there are any heart specific autoantibodies that only 
target the heart and could be used as diagnostic and prognostic markers? 
Additionally, is there any genetic predisposition for cardiac damage in SLE patients? 
Further studies are needed to explore answers to these questions. 
1.4 Objectives of the study 
The main aim of this project is to explore the possible pathogenesis of 
cardiovascular involvement in lupus patients. I hypothesize that there are certain 
heart reactive autoantibodies (HRAA) in SLE patients’ serum, which target heart 
Introduction 
 53
proteins and cause myocardial damage. I will screen non-selected SLE patients and 
other non-SLE patients as well as normal control subjects to identify novel 
antibodies against heart membrane antigens. A comprehensive 2 dimensional and 
Doppler echocardiographic study will be conducted in the lupus patients’ cohorts to 
elicit any association between echocardiographic manifestations and HRAA 
positivity. I will try to identify the antigens and explore the functions of these 
proteins and develop ELISA for early diagnosis of cardiovascular involvement in 
lupus patients.  
Additionally I will also explore the prevalence of genetic polymorphisms of the 
promoter gene of IL-18, assay the protein levels and elicit association of present. 
My study will help to better understand the mechanisms as to how the 
cardiovascular abnormalities developed in SLE patients and the roles of 
autoantibodies played in the progression of the disease. It may provide an early, 
new diagnostic approach for lupus patients who will develop cardiovascular 
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2.1 Heart reactive autoantibody study 
2.1.1 Recruitment of patients and normal controls and collection of clinical 
data 
One hundred and nine SLE patients were included in the study, all of which fulfill 
the 1997-updated ACR criteria (Hochberg 1997). The study protocol was approved 
by the institutional review board (IRB SGH #82/2005). Patients with 
anti-phospholipid syndrome (APS), rheumatoid arthritis (RA), osteoarthritis (OA), 
polymyositis (PM) and acute myocardial infarction (AMI) were also recruited as 
non-lupus patient controls. They satisfy the current diagnostic criteria for their 
corresponding diseases. Healthy controls were recruited from among healthcare 
workers and medical undergraduates. 
Five microliters of peripheral venous blood was obtained under aseptic conditions 
during the patients’ routine blood draw. Sera were collected from clotted blood 
using standard protocol. All sera were kept in -80°C freezers until further 
experiments. 
Relevant clinical data - age, sex, ethnic group, disease duration, age at disease onset, 
ACR criteria present, pulmonary hypertension, valvular heart disease, 
cardiomyopathy, hypertension, peripheral vascular disease, coronary artery disease, 
hypercholesterolaemia, anti-nuclear antibodies, anti-dsDNA antibodies, extractable 
nuclear antibodies (Sm, RNP, SSA/Ro, SSB/La), antiphospholipid autoantibodies 
(anti-cardiolipin, lupus anticoagulant, VDRL) were recorded by chart review using 
a standard protocol. Patients who have the following situations are excluded from 
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this study: 1) those with another rheumatologic condition; 2) those who refuse 
venepuncture; 3) those who are pregnant at the time of enrollment, 4) those with 
active hemolysis or with Hb less than 8g/dl; 5) those with concomitant congenital 
heart or rheumatic valvular diseases; 6) those who do not understand the informed 
consent form e.g. active neuropsychiatric lupus; 7) patients more than 60 years of 
age. 
Antinuclear antibodies (ANA) were screened by indirect immunofluorescent test 
with a positive titer of 1:80 considered significant. Autoantibodies against Smith 
(Sm), ribonucleoprotein (RNP), SSA/Ro, SSB/La, and cardiolipin (IgG and IgM 
isoforms) antigens were determined by ELISAs and lupus anticoagulants detected 
by the aPTT, prothrombin time (PT), modified Russell viper venom screen 
(MRVVT), and a hexagonal (II) phase phospholipid assay. Biological false-positive 
VDRL tests were determined by microflocculation tests and confirmed by 
Treponema Pallidium Particle Agglutination tests. 
2.1.2 Sources of organ samples 
Two 8-week old female BALB/c mice were sacrificed according to accepted 
protocol and used for extraction of membrane proteins from the following organs - 
brain, heart, kidneys, liver and spleen. The hearts of pig, chicken, duck, frog and 
fish (Indian Mackerel-Rastrelliger kanagurta ) were purchased from local markets. 
Human heart membrane proteins (normal adult male) were purchased from 
BioChain, USA. 
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2.1.3 Membrane protein extraction 
All chemicals were purchased from Sigma Aldrich, unless otherwise mentioned. 
The frozen/fresh tissue was thawed and cut into small pieces, then homogenized by 
mortar and pestle in 1xPBS containing a cocktail of proteinase inhibitors (5μg/ml 
leupeptin, 5μg/ml approtinin and 1mM phenyl methyl sulfonyl fluoride). Heart 
lysates were further homogenized using syringe and needles method (starting from 
19G and gradually reduced in bore sizes to 27G), followed by centrifugation at 
13,000xg for 10 minutes at 4°C to separate the water-insoluble pallet. Repeated 
washings with 1x PBS containing cocktail of protein inhibitors were done until 
proteins were not detected in wash buffer using BioRad protein assay. The 
water-insoluble protein was dissolved in 1xPBS containing 6M urea together with 1 
mM phenylmethyl sulfonyl fluride and incubated on shaker for 15 minutes at room 
temperature. The urea-soluble protein was separated using centrifugation at 
13,000xg for 30 minutes at room temperature. BioRad protein assay was used to 
measure the protein concentrations and aliquoted proteins were kept in -80°C 
freezers until future use. 
The membrane proteins from different mouse tissues (brain, heart, liver, kidney and 
spleen) were extracted using the protocol described. The same protocol was also 
used to extract heart proteins from different species (pig, duck, chicken, frog and 
fish). 
2.1.4 Immunoblotting  
The sodium dodecyl sulphate-polyacrylamide gel electrophoreses (SDS-PAGE) 
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were prepared using analytical comb or preparative comb according to the needs of 
experiments. The membrane proteins (20μg proteins per well for analytical comb or 
200 μg proteins per well for preparative comb) were denatured and separated in 
20% denatured SDS-PAGE gel. Upon completion of protein separation, the 
polyacrylamide gels were either visualized with Coomassie blue or transferred to 
Hybond nitrocellulose membrane (Amshersham). Coomassie Brilliant Blue R-250 
(BioRad) was compatible with Mass Spectrometry (MS) analysis. 
The electrophoretic transfer of separated proteins to nitrocellulose membrane was 
performed at 100 constant Volts for two hours using buffer transfer tank in cold 
room. The nitrocellulose membrane, on which the proteins were transferred, was 
incubated in blocking solution (3% scanned milk powder in 1xTBS-T; 1xTBS 
containing 0.1% Tween 20) on shaker for one hour at room temperature to block 
non-specific reactions prior to sample incubation. Depending on the purpose of 
experiment, nitrocellulose membrane with proteins separated using analytical 
combs were incubated with samples while those with proteins separated using 
preparative combs were cut into strips and incubated with samples separately. The 
samples diluted at 1:200 in blocking solution were incubated with membrane on 
shaker overnight at 4°C. Membranes were washed by 1xTBS-T thrice with 10 
minutes, soaking while shaking between washes. The membranes were further 
incubated with goat anti-human IgG conjugated with Alkaline Phosphatase 
(Chemicon) diluted in blocking buffer 1:10,000 on shaker for one hour at room 
temperature. The membranes were, after incubation, washed again with 1xTBS-T 
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thrice with 10 minutes, shaking between washes. The 
5-Bromo-4-Chloro-3'-Indolyphosphate p-Toluidine/Nitro-Blue Tetrazolium 
Chloride (BCIP/NBT) substrate (Zymed) was used to visualise the positive protein 
bands on the membranes. When optimal colour developed, the substrate was 
removed, membranes dried and documented.  
2.1.5 Detection of heart reactive autoantibody (HRAA)  
 Sera samples from lupus patients, patients with other rheumatic diseases and 
healthy individuals were screened for HRAAs using membrane proteins extracted 
from mouse heart as antigens. The immunoblotting screening was performed using 
20% SDS-PAGE for higher resolution. The western blot analyses were repeated at 
least twice to confirm the results. One strongly positive and one negative sera were 
selected as test controls for further immunoblotting experiments using membrane 
proteins extracted from different mouse tissues (liver, brain, spleen and kidney). 
These two representative samples were again used as test controls in 
immunoblotting experiments using heart membrane proteins extracted from 
different animal species (pig, chicken, duck, quail, frog, fish) and with human heart 
membrane proteins.  
2.1.6 Two-dimensional (2-D) gel electrophoresis 
Prior to 2-D gel electrophoresis, the water-insoluble pellet was dissolved in 2-DE 
sample solubilization buffer containing 6M urea, 50mM DTT, 4% CHAPS, 0.2% 
carrier amphyolytes (1:2 Bio-lyte 7/9:Bio-lyte 8/10), 0.0002% Bromophenol Blue. 
Protein concentration was determined by BioRad RC DC protein assay.  
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100 μg of heart membrane proteins each were applied onto a pair of pH 7-10, 7cm 
ReadyStrip IPTG strip (BioRad) during passive rehydration step. The first 
dimension (Isoelectric Focusing) was done for 8000 V-hr at 15°C on Protean IEF 
cell (BioRad). Upon completion of first dimensional gel electrophoresis, the strips 
were equilibrated in SDS-buffers prior to second dimensional gel electrophoresis. 
The second dimensional separation was done in 10% SDS-PAGE. The paper wick 
soaked with mouse heart membrane proteins was added next to IPG strip when the 
strip was loaded onto SDS-PAGE gel. Upon completion of second dimensional gel 
electrophoresis, one was visualized with commassie staining and the other gel was 
used for immunoblotting with HRAA-positive serum. Immunoblotting was 
performed according to protocol described earlier.   
The immunoblot-matched gel spots were punched from commassie-stained 
polyacrylamide gel and sent for peptide mass finger-printing (PMF) using 
MALDI-TOF-MS (matrix-assisted laser desorption ionization- Time of Flight - 
Mass Spectrometry) at Agenica Research Pte Ltd, Singapore.  
2.1.7 Peptide mass fingerprinting 
Peptide mass fingerprinting was done using the MALDI-TOF-MS analysis. Briefly, 
the commassie-stained gel spots were destained with freshly prepared destaining 
buffer (5 μl of 30mM potassium ferricyanide and 5μl of 100mM sodium 
thiosulfate). The gel spots were washed properly and incubated overnight with 
trypsin (Promega). The trypsin-cleaved peptides released by sonication were 
desalted by ZipTip μ-C18 (Millipore).  The peptides together with 1 μl of matrix 
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mix containing 5mg/ml Alpha-Cyano-4-Hydroxycinnamic Acid (CHCA) and 
5mg/ml 2,5-dihydroxybenzoic acid (DHB) were loaded onto MALDI plate. The 
MS analysis was done by the curved field reflectron instrument Axima CFR-plus 
(Kratos, Shimadzu). The MALDI mass spectra were matched with Swissport 
and/or NCBI protein databases for known protein identification.  
2.1.8 Calculation of molecular weights  
The known molecular weights of prestained protein ladder (Fermentus) were 
plotted against corresponding distance from upper edge of the polyacrylamide gel 
in semi-log (log-linear) graph. Then the approximate expected molecular weights 
of heart membrane protein were calculated using linear regression. Similar 
observations were made in 10 western-blot results. The mean theoretical molecular 
weight of the autoantigen was calculated. 
2.1.9 Characterisation of the HRAA protein 
2.1.9.1 Western blot comparisons between lupus serum and troponin 
antibodies 
The mouse heart membrane protein was separated on 20% SDS-PAGE, followed by 
transfer to the Hybond nitrocellulose membrane (Amersham) as described above. 
Goat anti-human cardiac troponin I and goat anti-human slow skeletal troponin I 
(Santa Cruz Biotechnology) as well as lupus serum were used as the first antibody 
to incubate with the membrane. The second antibody used for the former two were 
donkey anti-goat IgG conjugated with Alkaline Phosphatase (Santa Cruz 
Biotechnology). For the lupus serum, goat anti-human IgG conjugated with 
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Alkaline Phosphatase (Chemicon) was used as the second antibody. Gel staining 
was performed as described above and positive bands obtained were compared.  
2.1.9.2 Immunoprecipitation 
One hundred microgram of mouse heart protein was transfered to one 
microcentrifuge tube with 1ml PBS buffer. Five microliters of polyclonal antibody 
was added to cardiac troponin I (0.2mg/ml) (Santa Cruz Biotechnology) and 
incubated for 1 hour at 4oC. 20ul of the resuspended protein G PLUS-Agarose 
(Santa Cruz Biotechnology) was then added and incubated overnight at 4 oC on a 
rocker platform. 
Immunoprecipitates were collected after centrifugation at 2500 rpm for 5 minutes at 
4oC. The supernatant was carefully aspirated and precipitated with acetone. The 
pellet was washed 4 times with 1.0 ml PBS buffer. Each wash was followed by 
repeat centrifugation as described above. After the final wash, the supernatant was 
aspirated and discarded, leaving the pellet behind. The pellet was resuspended in 
40uL 1x electrophoresis sample buffer and boiled for 2-3 minutes, and then 
analyzed by SDS-PAGE together with the collected supernatant. Western blotting 
was performed as described above. 
2.1.9.3 Competitive binding by human cardiac troponin I proteins 
Human cardiac troponin I proteins were purchased at 0.4mg/ml from Abcam UK. 
The protein was incubated with lupus serum diluted at 1:200 at different 
concentrations: 1ug/ml, 10ug/ml and 50ug/ml. Mouse heart proteins were separated 
on 20% SDS-PAGE gel, followed by transfer to the nitrocellulose membrane. The 
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nitrocellulose membrane, on which the proteins were transferred, was incubated in 
blocking solution (3% scanned milk powder in 1xTBS-T; 1xTBS containing 0.1% 
Tween 20) on shaker for one hour at room temperature to block non-specific 
reactions prior to incubation with the prepared sera on shaker overnight at 4°C. 
Membranes were then washed by 1xTBS-T thrice with 10 minutes soaking, and 
shaking between washes. The membranes were further incubated with goat 
anti-human IgG conjugated with Alkaline Phosphatase (Chemicon) diluted in 
blocking buffer 1:10,000 on shaker for one hour at room temperature. The 
membranes were, after incubation, washed again with 1xTBS-T thrice with 10 
minutes shaking between washes. The 5-Bromo-4-Chloro-3'-Indolyphosphate 
p-Toluidine/Nitro-Blue Tetrazolium Chloride (BCIP/NBT) substrate (Zymed) was 
used to visualize the positive protein bands on the membranes. When optimal color 
developed, the substrate was removed, membranes dried and documented.  
 2.1.10 Statistics 
Chi-square test and Fisher’s exact test were used to analyze data to calculate P 
value.  A value of P<0.05 was considered statistically significant. 
 
2.2 Echocardiography  
2.2.1 Patients 
One hundred and nine patients were involved in HRAA study and the 
echocardiography study. All of them satisfy the ACR criteria for classification of 
systemic lupus erythematosus and are followed-up by the investigators. Relevant 
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clinical data including age, sex, ethnic group, disease duration, age at disease onset, 
ACR criteria fulfilled are recorded by chart review using a standard protocol. The 
following clinical data were also included: pulmonary hypertension, valvular heart 
disease, myocardiopathy, hypertension, atherosclerosis, ischemic heart disease, 
hypercholesterolaemia, and presences of antiphospholipid autoantibodies. 
Presences of anti-SSA/Ro and anti-SSB/La autoantibodies, anti-Sm, anti-RNP, 
lupus anticoagulant antibodies, antinuclear autoantibodies (ANA) were also 
recorded. All the autoantibodies were assayed in Department of Pathology, 
Singapore General Hospital using enzyme linked immunosorbent assay (ELISA) or 
indirect immunofluorescent test.  
2.2.2 Echocardiography 
A comprehensive 2-dimensional and Doppler echocardiography study was 
performed using a commercially available ultrasound machine (Vivid 7 Dimension, 
GE Healthcare, Milwaukee, WI) with a broadband phased array probe. 
Morphologic and functional information on involved valvular, myocardial and 
pericardial structures were collected. Indices of left ventricular systolic and 
diastolic function and right ventricular function were measured. Myocardial 
velocities were recorded by activating the color tissue Doppler function to record 
low velocity, high intensity myocardial signals at high frame-rate (>140MHz). The 
imaging angle was adjusted to ensure a parallel alignment of the beam with the 
myocardial segment of interest. All images were saved digitally in raw 
radiofrequency data format to DVD for offline analysis. 
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2.2.3 Doppler tissue imaging and strain rates measurements 
Using dedicated software, longitudinal velocities were obtained at the annulus and 
midsegments of the inferoseptal and anterolateral walls in the apical 4-chamber 
view, and radial velocities from the midsegments of the anterolateral and inferior 
walls in the parasternal short axis view.  
Peak systolic, early and late diastolic velocities and the ratio of the mitral E to early 
diastolic mitral annular velocities (E/E’) were obtained. Strain rate curves were 
extracted from tissue Doppler imaging data by placing a 5-10mm sample bar on the 
myocardial layer of the same region and the velocity measurements. Peak systolic 
and diastolic strain rates can then be read off the automatically generated strain rate 
curves. 
2.2.4 Statistics 
Statistical analyses were performed using software (SPSS 12.0 for Windows). 
Values were presented as mean ± SD. Independent t test was used to explore the 
group differences. Pearson’s correlation test was used to find the correlation 
between variables. Differences were considered statistically significant if the P 
value was less then 0.05.  
 
2.3 Interleukin 18 and cardiac involvements in SLE 
2.3.1 Patient recruitment and sample preparation: 
One hundred and thirteen Chinese SLE patients from the Department of 
Rheumatology and Immunology, Singapore General Hospital, Singapore were 
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recruited for the present study. They fulfilled the ACR criteria for the classification 
of SLE. Two hundred and eighteen Chinese healthy normal individuals were 
recruited from among laboratory personnel, undergraduates, medical and nursing 
staff, and blood donors. Consent was obtained prior to venepuncture. About 5 ml of 
peripheral venous blood was collected under aseptic conditions into 
sodium-citrated tubes and processed within the same day. This cohort of lupus 
patients is not identical to the HRAA/Echocardiography study cohort.  
2.3.2 Genomic DNA extraction 
The genomic DNA was extracted using a salting-out method. The purity and 
concentration of DNA was determined using spectrophotometry. Following 
deproteinization, the quality of DNA was reflected by a consistent ratio of 1.8 to 2.0. 
The coded genomic DNA solution was stored at 4 oC. 
2.3.3 Specific Sequence Primer PCR 
The –137 single-nucleotide polymorphisms were detected using sequence specific 
polymerase chain reaction described by Giedraitis et al (Giedraitis et al. 2001). A 
common reverse primer 5'-AGGAGGGCAAAATGCACTGG-3' and two sequence 
specific forward primers 5'-CCCCAACTTTTACGGAAGAAAAG-3' and 
5'-CCCCAACTTTTACGGAAGAAAAC-3' were used. An amplification product 
of 261-bp was detected. A control forward primer 
5'-CCAATAGGACTGATTATTCCGCA-3' was used to amplify a 446-bp 
fragment covering the polymorphic site to serve as an internal positive 
amplification control.  
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2.3.4 Restriction Fragment Length Polymorphisms (RFLP) analysis 
For the –607 single-nucleotide polymorphisms, restriction fragment length 
polymorphism analysis was used to genotype the polymorphism. Generally, PCR 
for genotyping was performed with mutated primers: the forward primer 
5’-GTTGCAGAAAGTGTAAAAATTAGTA-3’ introduced a restriction site for 
Rsa I enzyme. The reverse primer was: 5’-TAACCTCATTCAGGACTTCC-3’. 
Biometra T3 thermocycler was used in PCR with the following conditions: 1 cycle 
of 95oC for 5 minutes followed by 35 cycles denaturing at 94 oC for 10 seconds, 
annealing at 55oC for 30 seconds and extension at 72oC for 30 seconds. The final 
extension step was done at 72oC for 10minutes. 30ul of PCR reaction contained 
50ng genomic DNA, 0.2uM each of forward and reverse primers; 0.1mM of dNTPs, 
1x reaction buffer and 0.2 units of DyNAzyme TM II DNA polymerase (FinnZymes). 
After confirmation of the success of PCR process, 6ul of PCR product was 
incubated with RsaI enzyme and the buffer recommended by the supplier for 60 
minutes at 37oC. Visualization of RFLP was done in Ethidium Bromide stained 3% 
aragose gel in 0.5x TBE buffer. 
2.3.5 Enzyme-linked immunosorbent assay (ELISA) for circulating 
Interleukin 18 levels in SLE patients 
Plasma IL-18 concentrations of randomly selected 76 SLE patients and 113 control 
subjects were measured by enzyme-linked immunosorbent assay (ELISA) using the 
human bioactive IL-18 ELISA kit (Medical and Biological laboratories, Nagoya, 
Japan).   
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2.3.6 Statistics 
Data were analyzed by Statistical Package for Social Science (SPSS) software 
(version 12.0). The allelic, genotypic frequencies of the IL-18 promoter gene 
polymorphisms in SLE patients and controls were compared using Chi-square test 
(X2) test and a corrected P (Pc) value of <0.05 was considered statistically 
significant. The Fisher’s exact test was used if any of the cells contains less than 5% 
of the cohort analysed. The Bonferroni method was used to correct for multiple 
testing. Expected population genetic frequencies were calculated using the 
















3.1 Patient demographics (HRAA study) 
One hundred and nine lupus patients were recruited into the study. As showed in Table 3, 
there are 97 females and 12 males with the Female/Male ratio of 8:1. The average age is 
39.6 years and the average disease duration is 8 years.  
As showed in Table 4, the lupus patients had the following ACR criteria: abnormal titers 
of antinuclear antibodies (96%), immunological disorder (91%), hematological disorder 
(77%), arthritis (68%) and renal disorder (46%) followed by the remaining ACR criteria 
(9-41%)   
Non-lupus patients included 55 primary anti-phospholipid syndrome (APS) patients, 42 
rheumatoid arthritis (RA) patients, 15 osteoarthritis (OA) patients, 6 polymyositis (PM) 
and 50 myocardial infarction patients. The female: male ratio is 1:1. And there are 124 
Chinese, 17 Malay and 27 Indians. 
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Table 3. Demographic data of controls, lupus and non-lupus patient cohort. 
 
__________________________________________________________________ 
Lupus (n=109)                                         
  Female: Male ratio                        8: 1  
  Mean Age (range)                       39.6 yrs (29 – 50) 
 Race      Chinese         81  
           Malay        17 
 Indian          8 
                             Filipino                  1 
                          Myanmese          2 
  Average disease duration (range) 8 yrs  (1-30 yrs) 
 
Non-Lupus (n=168)* 
 Female: Male ratio                               1: 1 
  Mean Age (range)                        52 yrs (21 - 81) 
 Race     Chinese          123  
         Malay             18 
        Indian             27 
 
Controls (n=120) 
    Female: Male ratio                         2.3: 1 
  Mean Age (range)                              35 yrs (21 - 41) 
 Race       Chinese          95  
           Malay    17 
          Indian      8 
 
* Non-lupus cohort include 55 primary anti-phospholipid syndrome, 42 rheumatoid 
arthritis, 15 osteoarthritis, 6 polymyositis and 50 myocardial infarction patients 
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 Table 4.  ACR criteria presentation of lupus patients at diagnosis (n=109) 
 
ACR Criteria Number of Patients Percentage (%) 
Malar Rash 41 40 
Discoid Rash 12 12 
Photosensitivity 40 39 
Oral Ulcers 34 33 
Arthritis 70 69 
Serositis 16 16 
Renal Disorder 47 46 
Neurologic Disorder 9 9 
Hematologic Disorder 78 76 
Immunologic Disorder 93 91 




3.2 Prevalence of HRAAs in lupus patients, non-lupus patients and healthy controls 
Thirteen (12%) lupus patients showed a positive band on immunoblot with mouse heart 
lysate as antigen (Figure 5). The 168 non-lupus patients and 50 myocardial infarction 
patients did not show a similar band, nor did the 120 normal controls. However, the 6 
polymyositis patients showed a positive band, which is of a lower molecular weight 
(subsequent experiments established this lower band as skeletal troponin I protein). Thus 
HRAA reacting with mouse heart membrane proteins was found only in lupus patients, 
but not in healthy individuals and non-lupus patients (P<0.00001) (Table 5). 
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Table 5. HRAA in controls, lupus and non-lupus groups  
 
 Number Negative Positive 
Control group 120 120 0 
Lupus patients* 109 96 13 
Non-lupus patients 168 168 0 





   
Figure 5. Identification of Heart Reactive Autoantibody (HRAA).  
Mice heart membrane proteins were separated on 20% SDS PAGE gel and blotted with 
various sera samples, followed by coomassie blue staining. Lane 1 – lupus serum with 
positive protein band indicating presence of anti-cTnI antibody, Lane 2 – lupus serum 
with no protein band, Lane 3 – serum from patient with rheumatoid arthritis, Lane 4 – 
serum from healthy individual. M indicates the molecular weight marker. 




Patients with HRAA-positivity and those without, did not show differing clinical 
manifestations, neither are there significant differences in age, ethnic distribution or 
disease duration (Table 6). The autoantibodies profiles of the lupus patients are shown in 
Table 7. No difference exists between the autoantibodies profiles of HRAA positive 
group and negative groups. There are also no differences of the distribution of diabetes 
mellitus, hypertension or hyperlipidemia in SLE patients with or without HRAA 













Female to male ratio 8.6:1 5.5:1 0.59 
Mean age (years) 39.7 ± 10.3 38.5 ± 11.0 0.40 
Ethnicity          0.59 
Chinese 73 (76%) 8 (62%)  
Malay 14 (15%) 3 (23%)  
Indian 6 (6%) 2 (15%)  
Others 3 (3%) 0 (0)  







Table 7.  Autoantibody profiles of SLE patients positive and negative for HRAA  
 
 
HRAA negative     
(N=96) 
HRAA positive        
(N=13) 
P value 
 N % N %  
ACA (IgG) 25 26% 5 38% 0.24 
ACA (IgM) 18 19% 4 31% 0.31 
False-positive VDRL 4 4% 2 15% 0.10 
Lupus anticoagulant 14 15% 3 23% 0.43 
Ro 33 34% 5 38% 0.77 
La 15 16% 0 0 NA 
Sm 18 19% 3 23% 0.71 
RNP 26 27% 5 38% 0.39 
 
ACA, anticardiolipin antibodies; RNP, Robonucleoprotein antibody, SSA, Sjogen’s 
syndrome A antibody; SSB, Sjögen’s Syndrome B antibody; Sm, Smith antibody; VDRL, 












N % N % 
P value 
Diabete milletus 4 4% 0 0 1.0. 
Hypertension 17 18% 2 15% 1.0 





3.3 Tissue and species specificity of HRAA 
The immunoblotting experiments were carried out using membrane protein lysates from 
different mouse organ tissues (brain, liver, kidney and spleen). The results are shown in 
Figure 6. The antibody that reacted with heart membrane proteins are not detected with 













Figure 6. The HRAA is heart-specific.  
The immunoblotting experiment was carried out using membrane protein lysates from 
different mouse tissues (lane1: mice brain membrane proteins, lane 2: mice heart 
membrane proteins, lane 3: mice liver membrane proteins, lane4: mice kidney membrane 
protein, and lane 5: mice spleen membrane proteins.) The HRAA were showed only in 
heart membrane proteins, which suggests that the antibody is organ-specific. 
 
The same experiments were carried out using heart lysates of different animals. It is 
interesting to note that HRAAs targeted heart membrane protein lysates of mammalian 
origin e.g. pig, mouse and human, but did not react with those of other species such as 
avian, fish and amphibian (Figure 7). Using human heart membrane proteins as antigens 
produced similar bands as that of mouse heart membrane proteins. Random samples 
comprising positive and negative samples showed concordance in immunoblotting 
 




results with human or mouse heart antigens. Hence the mouse heart antigens were used 
as a surrogate for the human heart antigens.  
 
Figure 7. Immunoblotting results of HRAA against heart membrane protein 
extracted from different species.  
Lane 1: pig heart membrane protein; lane 2: mice heart membrane protein; lane 3: human 
heart membrane protein; lane 4: chicken heart membrane protein; lane 5: frog heart 
membrane protein; lane 6: fish heart membrane protein. 
35kDa 
24kDa 
    1               2              3              4             5               6   
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3.4 Peptide Mass fingerprinting of heart antigens reactive to HRAA 
We used 2-D gel electrophoresis to separate the HRAA. The matched protein spot of 
commassie blue stained SDS-PAGE was sent for peptide mass fingerprinting using 
MALDI-TOF-MS analysis. The trypsin-cleaved peptides mass spectra were matched 
against public protein databases (NCBI and Swissport). The positive spot was identified 
as cardiac troponin I (gi/136210 which now is currently termed  gi/109890854) which 
has the highest score 170 and expect is 3.5e-011.  Ions score is -10*Log (P), where P is 
the probability that the observed match is a random event. Protein scores greater than 78 




Figure 8. Two dimensional electrophoresis detection of mouse heart membrane 
proteins recognized by systemic lupus erythematosus patient’s serum. A, Two 
dimensional map of mouse heart membrane proteins. The proteins were resolved by IEF 
on the IPG (pH range from 3-10) and with a 12% SDS PAGE Gel stained with coomassie 
brillant blue 250. Molecular weight markers were shown on the right. B, 
Two-dimensional immunoblot was probed with SLE serum. The arrow pointed spot 
represented SLE-specific activity. The spot, located recurrently on the gel, was then 
analyzed by MALDI-TOF_mass spectrometry. C , the resulting spectra for the spot were 
used for database searching. 
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3.5 Confirmation of cardiac troponin I  
3.5.1. Comparison of  the western blotting images 
As shown in Figure 9, the positive band recognized by the commercial cTnI antibody 
was similar to the one recognized by the SLE patients’ serum. And there was no positive 













Figure 9. Serial immunoblots using varying anti-cTnI antibodies and lupus sera 
dilutions.  
Antigen is mouse heart lysate. Lane 1 - 1:200; Lane 2 - 1:400; Lane 3 - 1:800; Lane 4 - 
1:1,600; Lane 5 – 1:3,200. Lupus sera were diluted at 1;200 (Lane 6) and 1:300 (Lane 7). 










 Figure 10 showed that anti-cTni antibody cross reacts with slow skeletal TnI (ssTnI). 
However the protein band is of a lower molecular weight. As shown in Figure 11, the 
antigen recognized by SLE serum was depleted by immunoprecipitation with antibodies 
to cardiac troponin I (cTnI) in the supernatant, but was recoverable in the pellet fraction, 









Figure 10.  Immunoblots showing bands indicate presence of anti-cardiac TnI 
(cTnI) and skeletal TnI (sTnI) in lupus and polymyositis patients.  
Lane 1: anti-cTnI-negative lupus patients with myositis, Lane 2: anti-cTnI-positive lupus 
patients with active disease, including myositis, Lane 3: patient with polymositis, Lane 4: 
anti-cTnI-positive lupus patient with no myositis. 
 












Figure 11. Immunoprecipitation of the mouse heart proteins using antibody against 
cardiac Troponin I (cTnI). The antigen recognized by SLE serum was depleted by 
immunoprecipitation with antibodies to cTnI, but was recoverable in the pellet fraction. 
Lane 1, mouse heart protein lysate; lane 2, pellet, lane 3, supernatant
1            2                   3 
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3.5.3. Competitive western blotting 
The results of the competititive western blotting were shown in Figure 12. The intensity 
of the band recognized by SLE serum was weaker in a dose-independent manner by 
addition of recombinant human cTnI protein, whereas the lower bands were not affected. 





Figure 12. Competitive western blotting. The intensity of the band recognized by SLE 
serum was weaker in a dose-independent manner by addition of recombinant human 
cTnI protein, whereas the lower bands were not affected. Lane 1: SLE serum (1:200 
dilution); Lane 2: SLE serum (1:200 dilution) with 1ug/ml cTnI protein; Lane 3: SLE 
serum (1:200 dilution) with 10ug/ml cTnI protein; Lane 4: SLE serum (1:200 dilution) 
with 50ug/ml cTn I protein; and Lane 5: blank.  





Table 9 details the M-mode, 2-dimensional and conventional Doppler echocardiographic 
findings in patients with and without anti-cTnI antibodies. Morphologic and functional 
LA and LV indexes were not significantly different between patients with and without 
anti-cTnI. LV systolic dysfunction (ejection fraction < 55%) was present in 1 
anti-cTnI-positive patient, a 21-year-old female with globally reduced LV ejection 
fraction (46%) of uncertain cause, and in 1 anti-cTnI-negative patient, a 31-year-old 
male with incidental non-compaction cardiomyopathy causing multiple regional wall 
motion abnormalities and mildly depressed ejection fraction (51%). Regional wall 
motion abnormalities were present in 3 anti-cTnI-negative patients and none of 
anti-cTnI-positive cases (P = 1.00). There were no discernable differences in right heart 
size and function between groups. Pulmonary hypertension (pulmonary artery systolic 
pressure > 40 mm Hg) was only encountered in anti-cTnI-negative patients. 
We performed a subgroup analysis in patients with SLE based on the presence or absence 
of autoantibodies e.g anit-SSA/Ro, Anti-SSB/La, Anti-Sm and Anticardiolipin 




Table 9. M-mode, two-dimensional, conventional Doppler and annular tissue 
velocity echocardiographic variables in SLE patients with and without anti-cTnI. 
 
 Anti-cTnI negative   
(N = 96) 
Anti-cTnI positive    
(N = 13) 
P 
 N or value % N or value %  
LV end-systolic dimension (mm) 29 ± 4  30 ± 5  0.25 
LV end-diastolic dimension (mm) 46 ± 4  48 ± 4  0.20 
LV ejection fraction (%) 68 ± 6  66 ± 8  0.56 
LV ejection fraction < 55% 1 1 1 8 0.11 
Regional wall motion abnormality 3 3 0 0 1.00 
Cardiac index (L/min/m2) 2.85 ± 0.66  2.86 ± 0.63  0.89 
LV mass index (g/m2) 81 ± 21  80 ± 26  0.56 
LA volume index (ml/m2) 25 ± 6  27 ± 10  0.42 
LA volume index > 30 ml/m2 16 17 5 38 0.13 
RV dimension (mm) 19 ± 4  18 ± 5  0.48 
RV systolic dysfunction      
RA volume index 20 ± 10  23 ± 8  0.12 
PA systolic pressure (mm Hg) 31 ± 11  29 ± 5  0.89 
PA systolic pressure > 40 mm Hg 5 5 0 0 1.00 
Mitral E/A 1.48 ± 0.52  1.30 ± 0.40  0.22 
Mitral deceleration time (ms) 164 ± 35  170 ± 18  0.35 
Isovolumic relaxation time (ms) 83 ± 16  86 ±12  0.67 
PV systolic/diastolic velocity ratio 1.13 ± 0.36  1.21 ± 0.29  0.21 
PV A reversal velocity (cm/s) 26 ± 14  24 ± 4  0.64 
Flow propagation velocity (cm/s) 55 ± 13  51 ± 12  0.40 
Septal annular systolic velocity 7.7 ± 1.4  7.7 ± 1.4  0.95 
Septal E’ velocity 10.2 ± 2.4  10.5 ± 2.3  0.92 
Septal E’/A’ 1.33 ± 0.42  1.27 ± 0.36  0.72 
E/E’ 7.61 ± 2.33  7.17 ± 1.83  0.87 
RV annular systolic velocity 12.0 ± 2.1  11.6 ± 1.5  0.69 
RV annular E’ velocity 12.8 ± 3.2  12.9 ± 2.9  0.95 
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Global myocardial tissue velocity, ε and SR data are as shown in Table 10. Indices of 
systolic function, including deformation, were not different between groups. 
Conventional diastolic function parameters were likewise not different between groups. 
Although both flow propation and early diastolic tissue (E’) velocities were expectedly 
lower in anti-cTnI-positive patients, these did not achieve statistical significance. 
However, anti-cTnI-positive patients had significantly reduced longitudinal early 
diastolic SR compared to anti-cTnI-negative patients. There were no significant 
differences in radial ε and SR.  
Stepwise linear regression was performed to analyze the influence of factors that may 
affect early diastolic longitudinal SR, apart from anti-cTnI antibody-positivity (Table 11). 
These covariates included age, disease duration, hypertension and renal disease. 
Longitudinal SR during early filling in SLE patients correlated with age (Spearman’s ρ = 
-0.27, P = 0.003) and presence of anti-cTnI antibody (ρ = -0.25, P = 0.008) but not 
disease duration, hypertension or renal disease (all P > 0.60). In a stepwise linear 
regression model, only anti-cTnI antibody positivity (P = 0.010) and age (P = 0.012) 
independently predicted reduced early diastolic longitudinal SR.  
Abnormalities of the mitral and aortic valve in SLE patients are documented in Table 12. 
There were no significant differences in either thickening or regurgitation between 






Table 10. Longitudinal (Longit) and radial myocardial tissue velocity, strain rate 
and strain indexes in SLE patients with and without anti-cTnI. 
 





 Longit Radial Longit Radial Longit Radial
Tissue velocity (cm/s)       
Systolic 4.2 ± 1.0 3.6 ± 0.7 4.2 ± 1.5 3.6 ± 0.8 0.85 0.95 
E’  6.4 ± 1.8 7.5 ± 2.2 6.1 ± 1.7 6.6 ± 1.2 0.43 0.093 
A’ 3.7 ± 1.2 1.8 ± 0.8 4.1 ± 0.9 1.8 ± 0.8 0.082 0.91 
Strain rate (s-1)       
Systolic 1.2 ± 0.3 2.1 ± 0.4 1.1 ± 0.2 1.9 ± 0.6 0.36 0.091 
Early diastolic 2.0 ± 0.5 5.5 ± 1.6 1.7 ± 0.3 5.3 ± 1.3 0.008 0.69 
Late diastolic 1.0 ± 0.4 1.4 ± 0.6 1.0 ± 0.2 1.2 ± 0.3 0.86 0.14 
Strain (%)       
Peak ejection 20 ± 3 54 ± 15 19 ± 3 48 ± 16 0.31 0.22 
End ejection 20 ± 3 54 ± 15 19 ± 3 48 ± 16 0.20 0.21 
Peak 20 ± 3 63 ± 25 19 ± 2 53 ± 16 0.30 0.18 
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Table 11.  Correlation of longitudinal strain rates with Anti-cTnI 
 
  L_SR_E Age Dur SLE HT Renal Anti-cTnI 
L_SR_E 1.00 -0.27 -0.04 0.08 -0.06 -0.25 
Age -0.27 1.00 0.35 0.33 -0.13 -0.04 
Dur SLE  -0.04 0.35 1.00 0.24 -0.07 -0.01 
HT 0.08 0.33 0.24 1.00 0.06 -0.02 





Anti-cTnI -0.25 -0.04 -0.01 -0.02 -0.05 1.00 
        
L_SR_E  0.003 0.36 0.21 0.28 0.008 
Age 0.003  0 0 0.10 0.36 
Dur SLE  0.36 0  0.007 0.23 0.46 
HT 0.21 0 0.007  0.26 0.42 
Renal 0.28 0.10 0.23 0.26  0.29 
Significance 
(P) 
Anti-cTnI 0.008 0.36 0.46 0.42 0.29  
 





Table 12. Valvular thickening and regurgitation in SLE patients according to 
anti-cTnI status. 
 





 N % N %  
Mitral valve thickening      
< 3 mm 84 88 10 77 0.39 
> 3 mm 12 13 3 23  
Mitral valve regurgitation      
None or mild 93 97 12 92 0.40 
Moderate or severe 3 3 1 8  
Aortic valve thickening      
Absent 80 83 11 85 1.00 
Present 16 17 2 15  
Aortic valve regurgitation      
None 86 90 13 100 0.60 




3.7 IL-18 results 
3.7.1 Clinical data  
There are 113 SLE patients and 218 healthy unrelated controls involved in the 
cytokine study. The ages of patients range from 15 to 74 years and for the control 
subjects, the ages range from 20 to 45 years. Both groups comprised individuals of 
Chinese descent. The female to male ratio in SLE patients and controls are 11.3: 1 
and 3.4:1 respectively. Randomly, 76 patients had their circulating IL-18 protein 
levels detected and also been screened for HRAA antibody. 
3.7.2 Allelic frequencies of IL-18 promoter gene polymorphisms at position 
-607 and –137 in SLE patients and controls 
The allelic frequencies of the Adenine (A) and Cytosine (C) at position –607 as well 
as Guanine (G) and Cytosine (C) alleles at position –137 were shown in Table 13. 
For position -607, the frequency of allele A was 0.2 while that of allele C was 0.8 in 
patient group. In control subjects, the frequency of allele A at position -607 was 
0.34 and 0.66 for allele C.  There was a significant difference between the 
distribution of the allelic frequency in SLE patients and normal controls for position 
-607 (P< 0.01).    
However, no significant differences at position–137 were found between the two 
groups. The frequency of alleles G and C were 0.83 and 0.17 respectively in 





Table 13. Allelic frequencies of IL-18 promoter gene polymorphisms at 
position-607 and –137 in SLE patients and controls 
 
 Patients (n= 226) Controls (n= 436) P-value 
 n Frequency n Frequency  
Position –607  
A 46 0.20 149 0.34 
C 180 0.80 287 0.66 
 
<0.01 
      
Position –137     
G 187 0.83 380 0.87 





3.7.3 Genotypic frequencies of IL-18 promoter gene polymorphisms at 
position -607 and -137 in SLE patients and controls 
The genotypic frequencies of the two single nucleotide polymorphisms (SNPs) 
were shown in Table 14. Eight patients had AA genotype and 32 controls showed 
AA genotype. Thirty patients had AC genotype while 85 controls had AC genotype. 
For CC genotype, 75 patients were among this subgroup compared to 101 controls. 
The differences reflected an increase of genotype –607/CC and a decrease of 
genotype –607/AC in SLE patients. The frequency of genotype –607/AA was also 




For position-137, the frequency of genotype CC showed a significant increase in 
SLE patients (n= 10, frequency is 0.09) when compared to control individuals (n= 2, 
frequency is 0.01) (Pc < 0.003). The other two genotypes were only slightly 
different without any statistical significance. Seventeen percent of patients and 24% 
controls showed CG genotype while 74% patients and 75% controls had GG 
genotype. The calculated genotypic frequencies (based on Hardy-Weinberg 
equilibrium) for position –607 are AA:0.04, AC:0.32 , CC:0.64 for SLE patients 
and AA:0.12, AC:0.45, CC:0.43 for normal controls ( Table 15).  For position –137, 
the frequencies are CC: 0.03, GC: 0.28, GG: 0.69 for SLE patients and CC: 0.01, 
GC: 0.23, GG: 0.76 for normal controls. And there is no significant difference 




Table 14. Genotypic frequencies of IL-18 promoter gene polymorphisms at 
positions -607 and -137 in SLE patients and controls. 
 
Patients (n=113) Controls (n=218)   
n Frequency n Frequency 
Pc 
AA 8 0.07 32 0.15 NS 
AC 30 0.27 85 0.39 0.048 
Position -607 
CC 75 0.66 101 0.46 <0.01 
       
Position -137 CC   10 0.09     2 0.01 0.003 
GC 19 0.17   52 0.24 NS  





Table 15. Expected genotypic frequencies of both SNPs based on 
Hardy-Weinberg equilibrium. 
 
  Patients Controls 
AA 0.04 0.10 
AC 0.32 0.43 
Position -607 
CC 0.64 0.48 
    
CC 0.03 0.02 
CG 0.28 0.23 
Position -137 




3.7.4 The correlation of IL-18 promoter gene polymorphisms and circulating 
IL-18 protein levels 
Levels of plasma bioactive IL-18 in SLE patients and normal controls was shown in 
Table 16. In the patients group, the concentrations of IL-18 bioactive protein for the 
6 patients who had AA genotype at position –607 was 75.33±66.72 (mean±SD) 
pg/ml while the 22 patients who had AC genotype was 214.2±139.3pg/ml. The 48 
patients with CC genotype had 217.3± 165.3pg/ml. As shown in Figure13, 
significant differences were observed in the three subgroups (P < 0.02). In the 
control group, 21 subjects with AA genotype at SNP-607 had significantly lower 
IL-18 protein concentrations when compared to the 45 subjects with AC genotype 
and 47 with CC genotype (P< 0.002). The mean concentrations for the three 
subgroups are 65.9pg/ml, 143.7pg/ml and 136.7pg/ml respectively (Figure 14). 
 
Table 16. Correlation between SNP-607 genotypes and plasma IL-18 protein 
concentrations 
  Number Mean±SD (pg/ml) Std. Error P value 
AA 6 75.3±66.7 27.2 
AC 22 214.2±139.3 29.7 
 Patients 
CC 48 217.3±165.3 23.9 
0.02 
      
AA 21 65.9±45.6 9.96 
AC 45 143.7±107.7 16.0 
Controls 






Figure 13.  Correlation between SNP-607 genotypes and IL-18 plasma protein 
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Figure 14. Correlation between SNP-607 genotypes and IL-18 plasma protein 
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3.7.5 Patients with anti-cTnI had higher circulating IL-18 protein levels.  
Among 76 lupus patients, there were 9 patients with positive anti-cTnI antibodies 
and the mean level of circulating IL-18 protein is 366.8pg/ml. In the anti-cTnI 
antibodies negative patients, the average plasma IL-18 protein level is 221.7pg/ml. 
Comparing the means of the two groups using 2-tailed t test, no stastitically 
significant difference was found. But the P value is 0.059, showing a trend that 
patients with positive anti-cTnI had higher circulating IL-18 protein levels.  




























Figure 15. Plasma IL-18 protein levels in SLE patients. Patients with positive 
anti-cTnI antibody had higher circulating IL-18 protein levels. The mean level of 















Thirty-five years ago, anti-heart antibodies detected by immunofluorescence were 
described and considered to represent a non-specific immunologic response to 
altered myocardial antigen released into the circulation following SLE myocarditis 
(Das and Cassidy 1973). However, it is challenging to find out the exact 
pathogenesis of cardiovascular involvements in SLE since multiple factors, 
including premature atherosclerotic coronary artery disease, coronary vasculitis, 
valvulopathy, systemic and pulmonary hypertension, renal impairment, anemia, 
calciphylaxis and adverse effects of medications may cause or contribute to the 
myocardial pathology, apart from immune complex-mediated vascular phenomena 
(Wijetunga and Rockson 2002). Circulating autoantibodies, including 
antiribonucleoprotein, anti-Ro (SS-A), and antiphospholipid antibodies have also 
been implicated (Doria et al. 2005; Wijetunga and Rockson 2002). 
In the present study a novel heart reactive autoantibody (HRAA) was characterized 
in SLE and a potential pathogenic role was explored. The 29 kDa antigen reacting 
with autoantibodies in lupus sera was identified as cardiac troponin I (cTnI). 
Anti-cTnI may cause subclinical myocardial damage or indicate chronic cTnI 
release in SLE patients. And the presence of the autoantibody was found to have 
correlation with circulating interleukin (IL)-18 levels in lupus patients.  
 
Increased levels of circulating interleukin (IL)-18, a proinflammatory cytokine, 
have proven to be a strong and independent predictor of cardiovascular death in 
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patients with coronary artery disease (Blankenberg S et al, 2002). Elevated levels of 
circulating IL-18 have also been demonstrated following acute myocardial 
infarction (Mallat et al. 2002) and in congestive heart failure (Naito et al. 2002; Seta 
et al. 2000a). In addition, increased levels of IL-18 and IL-18 receptor-α have been 
reported in myocardial tissues from patients with end-stage heart failure (Mallat et 
al. 2004).  
 
Several lines of evidence support IL-18 playing an important role in myocardial 
dysfunctions. Firstly, IL-18 induces synthesis of tumor necrosis factor (TNF)-α, 
IL-1β (Puren et al. 1998a), IL-6 and inducible nitric oxide synthase (Olee et al. 
1999), mediators that have all been associated with myocardial dysfunction (Brady 
1993; Brady et al. 1993). Secondly, IL-18 helps to activate T lymphocytes (Dao et 
al. 1998; Okamura et al. 1995) and induce neutrophilic cell infiltration (Leung et al. 
2001), as well as stimulation of intercellular adhesion molecule (ICAM)-1 (Kohka 
et al. 1998). Thirdly, it might also exert direct effects on the cardiomyocyte level. 
Both alterations in Ca2+ handling as well as reduced myofilament responsiveness 
to Ca2+ have been reported as mechanisms of myocardial dysfunction (Atar et al. 
1995a; Atar et al. 1995b). Fourthly, IL-18 may also play a role in cardiac 
remodeling by inducing hypertrophy of cardiomyocytes in vitro following 
activation of phosphatidylinositol 3-kinase (PI3K), phosphoinositide-dependent 
kinase-1 (PDK1), Akt, and GATA-4 signaling. Also, increased atrial natriuretic 
peptide (ANP) expression in isolated cardiomyocytes has been demonstrated after 
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IL-18 exposure (Chandrasekar et al. 2005a; Chandrasekar et al. 2005b; Seta et al. 
2000a). Fifthly, after short exposures to IL-18 in vitro, increased calcium transients 
(diastolic and peak) and reduced contractility of cardiomyocytes were observed 
(Woldbaek et al. 2003). Experimentally, daily injection of IL-18 in healthy mice 
induces LV contractile dysfunction and blunted β-adrenergic responsiveness to 
isoproterenol. Finally, IL-18 reduces the responsiveness of the myofilaments to 
Ca2+ (Woldbaek et al. 2005). Hence I postulate that specific IL-18 genetic 
polymorphisms which may lead to higher IL-18 productions may predispose lupus 
patients to cardiovascular involvement. 
 
I studied two single nucleotide polymorphisms at positions -607 and -137 of the 
IL-18 promoter gene in a cohort of Chinese lupus patients, and the concomitant 
protein levels in their circulation. The genotype SNP -607/CC was found to be 
significantly higher in Chinese lupus patients when compared to control individuals. 
Similarly, the genotype CC at position –137 was significantly higher in lupus 
patients. However the increase in the SNP-137/CC genotype’s frequency may be 
statistically significant but probably not clinically important, as the number of 
persons analyzed is small i.e. 10 patients and 2 controls. Interestingly, I 
demonstrated that SLE patients have significantly higher circulating IL-18 protein 
levels, consistent with previous reported studies (Amerio et al. 2002; Robak et al. 
2002). I also found that the -607/AC or -607/CC genotypes are associated with 
significantly higher concentrations of IL-18 bioactive protein in both the control 
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and lupus patient groups. This homozygous SNP -607/CC state is associated with 
higher transcription activity by the CREB protein, thus resulting in higher levels of 
IL-18 protein expression. This is consistent with our findings and those of several 
studies demonstrating elevated IL-18 protein levels in SLE patients (Amerio et al. 
2002; Robak et al. 2002).  
 
For position –607, Takada et al reported that in patients with sarcoidosis, the C 
allele at position –607, which was associated with higher IL-18 promoter activity, 
was a risk factor in the Japanese population (Takada et al. 2002). In RA patients, 
Sivalingam et al did not find C allele at position -607 to be associated with RA but 
that A allele at position -607, in the homozygous state, has a protective effect 
against development of rheumatoid arthritis (Sivalingam et al. 2003). My data 
indicate that higher promoter activity of IL-18 gene in SNP -607/CC is associated 
with SLE.   
I tested for an association between the presences of HRAA with the circulating 
IL-18 concentrations. Among the 74 lupus patients studied, 9 patients (12%) 
showed HRAA positivity. The mean concentration of circulating IL-18 protein is 
366.8pg/ml in the HRAA-positive group while the HRAA-negative patients have 
an average plasma IL-18 protein concentration of 221.7pg/ml. The P value of 0.059 
was not significant but showed a trend towards a clinical association. 
Hypothetically, higher IL-18 protein concentrations may induce the presence of 
HRAA, thus leading to cardiomyocyte damage or conversely HRAA may in some 
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way induce higher production of IL-18 protein. In the latter scenario, the HRAA 
may bind to the autoantigen, forming immune complexes, which may be deposited 
in cardiac tissue and trigger the activation of the complement cascade, chemotaxis 
and infiltration of immune cells, resulting in local inflammation. And IL-18 is one 
of the proinflammatory cytokines that are released into the circulation and further 
aiding the progression of the inflammatory process. This postulated mechanism of 
action is by no means certain. The hallmark of SLE is the production of multiple 
autoantibodies, and more than 100 different autoantibodies have been found in both 
human and animal lupus studies (Sherer et al. 2004). Among these autoantibodies, 
some may become “pathogenic” against self-antigens and result in (a) pathological 
change in the target organ and/or (b) binding of autoantibodies to target antigen that 
may lead to altered physiological function of target antigens (Tung 1994). 
Association between specific autoantibodies e.g. antiphospholipid antibodies, 
anti-SSA/Ro antibodies, anti-endothelial cell antibodies and cardiac involvement in 
lupus patients has been documented. The autoantibodies can affect heart tissue 
directly (anti-SSA/Ro and conduction abnormalities) or can trigger mechanisms 
leading to cardiac damage, for instance, aPL can contribute to cardiac damage 
through enhancing atherosclerosis phenomena, causing thrombosis of coronary 
arteries or starting an immune complexes mediated reaction.  
 
To elucidate the identity of the HRAA, we characterized the autoantigen as a 29 
kDa protein, present in mammalian heart tissues, and confirmed as cardiac troponin 
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I (cTnI) through 2D electrophoresis, mass spectrophotometry and competitive 
inhibition blottings. This finding is important as recent reports suggest that 
anti-cTnI antibodies are associated with various forms of cardiomyopathy. Cardiac 
troponin I is only present in cardiac muscles. Three isoforms of troponin I (Tnl) 
have been identified and are present as the major isoforms in cardiac muscle (cTnl), 
slow skeletal muscle (sTnl) and fast skeletal muscle (fTnl). There is a switch in Tnl 
isoform expression during cardiac development, and the major isoform in early 
fetal heart is slow skeletal Tnl, and this is replaced by cTnl late in fetal development 
(Sabry and Dhoot 1989a; Saggin et al. 1989). The cardiac isoform differs from 
those found in skeletal muscle in that it has an extended N-terminal sequence. This 
N-terminal region contains a serine residue which is phosphorylated during the 
phosphorylation-mediated regulation of contraction by P-adrenergic agonists in the 
heart (Solaro et al. 1976). The troponin complex regulates the actin-myosin 
interaction which plays a key role in the contraction of myocytes.  
 
Contraction is initiated when cytosolic calcium rises and binds the troponin 
complex and alpha tropomyosin. Calcium releases troponin I inhibition of 
actin-myosin interactions, and promptly actin becomes tightly bound to the myosin 
head. ATP then binds myosin and alters the conformation of the actin binding sites 
within myosin, so that the head domain is displaced along the thin filament. With 
ATP hydrolysis and release of ADP and Pi, force is generated (termed the power 
stroke), and the initial unbound conformation of myosin is restored (Rayment et al. 
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1993). Transmission of force generated by the sarcomere to the myocyte 
cytoskeleton occurs through a complex of molecules including cardiac myosin 
binding protein C, titin, dystrophin, and associated sarcoglycan peptides 
(Schiaffino and Reggiani 1996). When anti-cTnI in the SLE patient’s circulation 
binds to the cardiac troponin I (cTnI) protein, it may alter the physiological function 
of target cTnI protein. The complex contractile process may be disrupted, resulting 
in abnormalities of myocardium contraction and relaxation, finally leading to 
systolic or diastolic dysfunctions of the heart.  
 
Many studies have demonstrated the importance of cTnI in human heart. Gene 
mutations in cardiac troponin I (cTnI) account for up to 5% of genotyped families 
with familial hypertrophic cardiomyopathy (FHC) (Doolan et al. 2005; Mogensen 
et al. 2004; Richard et al. 2003). The mutation in the cTnI gene at codon 203, in 
which glycine is replaced by a serine residue (cTnI-G203S), has been previously 
reported to cause human FHC. This mutation also present in family members 
showing clinical features of FHC, and in some cases, associated with both 
supraventricular and ventricular arrhythmias (Kimura et al. 1997). The cTnI-G203S 
mutation is located near the COOH-terminal end of the cTnI protein, a region 
considered important in modulating actomyosin kinetics during unloaded sliding, 
potentially leading to enhanced cross-bridge cycling (Parmacek and Solaro 2004). 
Cellular studies also indicate that the cTnI-G203S mutation may enhance Ca2+ 
sensitivity of force generation (Deng et al. 2003; Elliott et al. 2000; Kohler et al. 
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2003) and disrupts interactions with partner proteins, resulting in intracellular Ca2+ 
dysregulation early in life (Tsoutsman et al. 2006). Recently, linkage analysis also 
identified cardiac troponin I (TNNI3) as the likely disease gene and mutations of 
the gene were also identified in families with restrictive cardiomyopathy and 
recessively inherited idiopathic dilated cardiomyopathy (Mogensen et al. 2003; 
Murphy et al. 2004). In mice, overexpression of a truncated form of cTnI induces 
dilatation of the heart (Murphy et al. 2000a; Murphy et al. 2000b). Okazaki et al 
(Okazaki et al. 2003) found heart specific autoantibodies against cTnI in PD1 
receptor-deficient mice that develop dilated cardiomyopathy (DCM). Using 
immunoelectron microscopy, they identified the subcellular location of cTnI on the 
outer surface of T-tubules, I-bands of sarcomers and surface of ventricular 
cardiomyocytes. They also demonstrated that administration of antibodies to cTnI 
in the normal mice caused increases in ESV and EDV of the left ventricle by 
weakening systolic function. Antibodies to cTnI enhance Ca2+ current as much as 
1.4-fold with a delay of 2 to 5minutes after addition of antibodies.  
More recently, Shmilovich et al (Shmilovich et al. 2006) demonstrated the presence 
of antibodies reactive with human cardiac troponin I in patients with DCM. These 
antibodies were found to reside in the sera of around 18% of patients with ischemic 
DCM, and around 15% of the patients with idiopathic DCM and none of the healthy 
subjects.  They also found that these antibodies appear specific as inferred from the 
competitive inhibition studies showing that fluid phase cardiac troponin I was 
capable of inhibiting the binding of purified “positive” IgG fractions reactive with 
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cTnI to the respective protein immobilized on solid phase surface. However they 
failed to demonstrate binding of these antibodies to cultured cardiomyocytes and its 
effects on Ca2+ currents. 
 
In the present study, I found autoantibodies against cardiac troponin I in around 
12% of unselected SLE patients and none of the healthy individuals, which is 
consistent with the results of Shmilovich et al. I also screened for the antibody in 
118 non-lupus rheumatic patients and in 50 acute myocardial infarction patients’ 
sera, but did not find the presence of the antibody. I hypothesized that the 
autoantibody reactive with cTnI reflects possible low-grade, chronic 
cardiomyocyte damage. Chronic release of cTnI into the circulation or repeated 
exposure of the immune system to the protein can lead to the formation of anti-cTnI 
antibodies. In acute myocardial infarction, the cardiac injury occurs abruptly and 
the concentration of cTnI decreases rapidly over a short time span. Once they are 
cleared from the circulation, they cannot drive the chronic production of anti-cTnI.  
To confirm the clinical utility of anti-cTnI antibody positivity, we performed 
echocardiographic measurements, including acquiring strain and strain rates 
indices, in our cohort of lupus patients. I demonstrated a higher occurrence of 
diastolic dysfunction in patients with anti-cTnI antibody positivity. Strain and strain 
rate indices showed that patients with the autoantibody have reduced early diastolic 
longitudinal strain rates. One report (Eriksson et al. 2005) suggests that this 
autoimmune response can manifest following AMI as “low recovery of added 
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cardiac troponin I” and mask the diagnosis if mid-fragment cTnI assays are used. 
Anti-cTnI antibodies were not however detected in our patients with AMI. Since 
only 10% of “low recovery” patients have markedly reduced recovery of cTnI , this 
discrepancy may be due to selection bias. “Low recovery” was also observed in 
healthy volunteers and may not therefore be specific to patients with AMI .  
I did not find significant differences in indices of systolic myocardial function 
between SLE patients with and without anti-cTnI antibodies, and only one 
anti-cTnI positive patient had a cardiomyopathic ventricle. Despite the up to 78% 
prevalence rate of myocarditis in autopsy series, clinically overt LV dysfunction is 
observed in ≤ 10% of SLE patients over the course of the disease (Doherty and 
Siegel 1985). Diastolic dysfunction is more typical and precedes contractile 
abnormality (Leung et al. 1990; Sasson et al. 1992). In the present study, long-axis 
myocardial SR imaging indicated reduced early diastolic relaxation rate in 
anti-cTnI positive patients; this was independently predicted by autoantibody status 
and age. Diastolic deformation imaging is less affected by preload alterations than 
transmitral flow velocities (Shimizu et al. 1998) and more sensitive than tissue 
velocity in the detection of abnormal myocardial relaxation. In patients with aortic 
stenosis, increase in early diastolic SR is apparent after aortic valve replacement 
despite lack of change in early diastolic tissue velocity (Iwahashi et al. 2006). 
Limited sampling and use of a shorter offset distance which is associated with 
greater noise may underlie the absence of demonstrable difference in radial early 
diastolic SR between anti-cTnI positive and negative SLE patients. Another 
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plausible explanation is offered by non-uniform muscle fiber architecture – 
long-axis deformation is mainly effected by longitudinally-oriented subendocardial 
and deeper oblique fibers (Greenbaum and Gibson 1981) which are susceptible to 
ischemia (Pellerin et al. 2003) and fibrosis (Bulkley and Roberts 1975; Henein et al. 
1995; Shan et al. 2000). Discordant longitudinal (or meridional) and radial function 
has been observed in obese non-hypertensive children (Di Salvo et al. 2006), 
hypertrophic cardiomyopathy (Hattori et al. 1992; Tabata et al. 2000) and patients 
with diabetic heart disease (Fang et al. 2004). Indeed, radial deformation may be 
exaggerated to compensate for reduced long-axis shortening (Fang et al. 2004). 
Thus, using validated techniques which are highly sensitive, subtle cardiac 
dysfunction associated with anti-cTnI can be detected. 
Anti-cTnI status did not predict the occurrence of either valvulopathy or pulmonary 
arterial hypertension. This is consistent with a recent report indicating that 
myocardial, valvular and pulmonary involvement in SLE may have independent 
pathogenesis (Farzaneh-Far et al. 2006). 
 
Myocardial deformation is the result of the complex interaction of intrinsic 
contractile force and extrinsic loading conditions applied to a tissue with variable 
elastic properties. Strain (ε) and strain rate (SR) indices are not direct measures of 
cardiac contractility---it may be affected by preload, afterload and contractility. 
However, the advantage of the SR/ ε indices for the study of diastolic events is that 
they offer very high real-time temporal resolution of deformation (sampling rates of 
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200 frames/s) compared with other noninvasive imaging modalities. This is 
important when studying diastole, as very high amplitude, short-lived deformations 
occur during this time period (this is especially true for untwisting and shape 
change during the isovolumic relaxation period) (Voigt et al. 2002). Recent clinical 
studies have shown SR/ε imaging to differentiate between control subjects and 
hypertensive patients, and among hypertensive patients, to help in differentiating 
between those with and without diastolic dysfunction (Yuda et al. 2002). Changes 
in the E’ peak velocities reflect regional impairment in relaxation whereas changes 
in compliance are better reflected by early diastolic changes in the regional strain 
curve. Data showed that the early diastolic myocardial velocities in the posterior 
wall relate inversely with the time constant of left ventricular relaxation (Oki et al. 
1997). A number of studies on the application of velocity, SR, and ε indices to both 
hypertrophic and dilated cardiomyopathies have been published (Abraham et al. 
2002; Weidemann et al. 2002). The present study suggest that the patients with 
anti-cTnI autoantibody have abnormal early diastolic longitudinal strain rates, and 
it is also the first report to describe the application of SR and strain in SLE patients. 
Tissue Doppler Imaging has revealed reduced left ventricular longitudinal function 
in many cardiac disease entities such as ischemic heart disease and hypertrophic 
cardiomyopathy. It complements assessment by the traditional two-dimensional 
echocardiography (Edvardsen et al. 2002; Kukulski et al. 2003; Sengupta et al. 
2005; Voigt et al. 2000). However few published studies have assessed longitudinal 
right ventricular function by TDI, although this has been done in cardiac 
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transplantation (Eroglu et al. 2005), Friedreich’s ataxia (Weidemann et al. 2003), 
arrhythmogenic right ventricular dysplasia (Herbots et al. 2003), and in primary 
pulmonary hypertension (Dambrauskaite et al. 2003). A recent study in 20 patients 
with pulmonary artery hypertension of varied etiology has assessed left and right 
ventricular longitudinal function by TDI, and found reduced peak systolic strain 
(SS) in the right ventricular free wall and ventricular septum but not in the left 
ventricular free wall (Lopez-Candales et al. 2005). No differences in TDI 
parameters were found between patients with or without anti-cTnI antibodies, but 
statistically significant differences in strain and strain rates indices were found 
between these groups. This may suggest that strain and strain rates indices are more 
sensitive in detecting early diastolic dysfunctions. SR/ε indices however do have 
limitations. The presence of signal noise in the velocity data set may confound 
regional calculations. Another source of problem is acoustic artifacts.  
There are some limitations in the study. The sample size and prevalence of 
anti-cTnI were relatively small, increasing the potential for Type II error. Due to the 
recognized gender disparity in SLE, the male: female ratio in patients and control 
groups were not readily matched. We did not study the presence of antibodies to 
troponin T in this study. Although a pathogenetic role for antibodies to troponin T is 
not excluded, one experimental study has shown that mice preimmunized with 
murine c-TnI before left anterior descending coronary artery ligation showed 
greater infarct size, more fibrosis, higher inflammation score, and reduced cardiac 
function while mice immunized with murine cardiac troponin T had little or no 
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inflammation and no death (Goser et al. 2006). 
Echocardiography was performed only in SLE patients and not normal controls. 
Therefore, the lack of comparative difference in most functional parameters does 
not indicate absence of dysfunction. Previous studies have shown abnormalities of 
both systolic and diastolic function or filling in patients with SLE (Leung et al. 
1990; Murai et al. 1987; Sasson et al. 1992), including reduced early diastolic tissue 
velocity (Cacciapuoti et al. 2005). Assessment of diastolic SR requires careful 
tracking of the region of interest throughout the cardiac cycle, as was done in this 
study. Since tracking was not performed in three-dimensional space, through-plane 
motion due to LV torsion could not be accounted for. However, this twist 
component is nearly orthogonal to the ultrasound beam and should not have greatly 
affected the results. Any limitation will also have systematically affected both 
anti-cTnI-negative and positive patients. 
Although the association between anti-cTnI antibodies and subtle cardiac 
dysfunction in SLE is highly plausible, our study does not clarify the mechanisms 
underlying this relation. Further study to clarify the interaction of anti-cTnI and 



















A novel 29-kDa heart reactive autoantibody was identified in lupus sera by 
immunoblots, and characterized as anti-cTnI (cardiac troponin I) antibody by 2-D 
electrophoresis and mass spectrophotometry of the mouse heart autoantigen. This 
was further confirmed by competitive inhibition assays. 
 
The prevalence of this antibody was found to be 12% in a cohort of 109 lupus 
patients and targets primarily mammalian heart tissue. Reduced early diastolic 
longitudinal strain rate is demonstrated in lupus patients with this autoantibody, 
indicating that the autoantibody may play an important role in cardiac damage. 
Higher production of interleukin 18 may be associated with patients positive for 
this autoantibody, which suggests that the presence of the autoantibody may induce 
the production of proinflammatory cytokine. 
 
The formation of anti-cTnI antibody is postulated to be due to the presence of 
chronic, low-grade cardiomyocyte damage and may represent sustained early 
cardiac damage in lupus patients. Clinically this antibody may serve as an early 
serological marker for cardiac involvement in lupus patients. 
 
Prospective studies should be carried out to further clarify the association and 
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